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ABSTRACT
Diabetes is becoming increasingly prevalent in North America, highlighting the 
necessity to create a renewable source of pancreatic P-cells for therapeutic purposes. The 
current study was undertaken to explore the hypothesis that ectopic expression of lineage­
determining transcription factors could generate a source of proliferative, homogenous 
pancreatic progenitor cells capable of subsequent differentiation to functional endocrine 
cell types, including P-cells. We validated transgenic systems for transgene delivery in 
HE SC and subsequently generated and analyzed gene expression patterns in transgenic 
cell populations engineered to constitutively express pancreatic transcription factors 
PAX4, PDX1, or NGN3. We demonstrate that ectopic expression of either PAX4 or 
PDX1 is not sufficient to specify pancreatic cells from human embryonic stem cells or 
definitive endoderm cells. In contrast, ectopic NGN3 expression specifies pancreatic 
endocrine cells from definitive endoderm. In conclusion, this study provides proof of 
principle of the ability to generate pancreatic endocrine cells using transcription factor 
overexpression in human embryonic stem cells.
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Diabetes mellitus is a chronic, metabolic disease of insulin insufficiency, affecting 
millions of people worldwide. During the disease state, there is a high level of glucose in 
the blood that results from the autoimmune destruction of insulin secreting P-cells in the 
islets of Langerhans, or from P-cell dysfunction. As a result of high blood glucose, 
patients present with frequent urination, increased thirst and increased hunger. Long-term 
effects of diabetes are cardiovascular disease, renal failure, and retinal damage (Group, 
1993). Recently, diabetes mellitus has become more prevalent, with 2.5 million 
Canadians having the disease in 2010. This rise in incidence can be attributed to factors 
such as increased obesity rates, and high rates of cardiovascular disease (Hotamisligil et 
al., 1993).
Despite the prevalence of diabetes, and the large financial burden to society, there 
is no renewable source of P-cells for therapeutic replacement. Currently, therapies are 
limited to insulin injection regimens and whole pancreas or pancreatic islet 
transplantation; however there is an insufficient source of donor tissue to keep up with 
demand for treatment (Bonner-Weir and Weir, 2005; Shapiro et al., 2000). This 
insufficient source of donor tissue has stimulated researchers to seek methods to generate 
a renewable source of functional P-cells.
1.1.1 Types o f Diabetes Mellitus
There are three predominant types of diabetes: type 1 diabetes, type 2 diabetes, 
and gestational diabetes. Type 1 diabetes affects 10% of the diabetic population. This
3
type of diabetes occurs due to a T-cell mediated autoimmune destruction of pancreatic 
islet P-cells, leading to insulin insufficiency (Bedossa et al., 1989). Individuals with Type 
1 diabetes are commonly diagnosed at an early age with a sudden onset.
Type 2 diabetes is the most common form of the disease, affecting approximately 
90% of patients diagnosed with diabetes. Type 2 diabetes is characterized by resistance 
to insulin action due to dyslipidemia, and subsequent reduction in insulin secretion with 
disease progression (Boden, 1996). This form of diabetes has classically presented in 
adults, however there is now an increased prevalence of children and adolescents that are 
being diagnosed. The prevalence of type 2 diabetes can be attributed to increased obesity 
rates within the population (Hotamisligil et al., 1993).
Gestational diabetes is defined as glucose intolerance with onset or first 
recognition during pregnancy (Metzger and Coustan, 1998). Gestational diabetes is 
present in 2 to 5% of pregnant women and is most commonly diagnosed in the third 
trimester. If left untreated, gestational diabetes can affect the health of both the mother 
and the baby. Women that have gestational diabetes are at a much higher risk of 
developing type 2 diabetes and cardiovascular disease following pregnancy, while their 
offspring tend to be large for gestational age and are at a greater risk for developing 
childhood obesity and resultant type 2 diabetes (Boney et al., 2005; Carr et al., 2006).
1.1.2 Treatments fo r  Diabetes Mellitus
Currently, the predominant therapy for both type 1 and type 2 diabetes mellitus is 
insulin injection regimens. This treatment consists of subcutaneous injections of
4
biosynthetic insulin. There are different types of exogenous insulin: rapid acting, short 
acting, intermediate acting, long acting and biphasic acting. These variations in 
exogenous insulin allow for patient-specific insulin injection regimes. Rapid acting 
insulin is used immediately prior to a meal, as it begins to work within 15 minutes. Short 
acting insulin is injected up to an hour prior to a meal, and lasts up to 8 hours following 
injection. Intermediate acting insulin must be injected at least an hour prior to a meal, 
and lasts for up to 16 hours. Intermediate acting insulin is commonly coupled with short 
acting insulin for complete daily coverage. Long acting insulin only requires one 
injection per day either in the morning or before bed, as it lasts for up to 24 hours. In 
addition to subcutaneous injections, the use of an insulin pump has become common, as it 
is capable of providing a constant drip of insulin throughout the day (Group, 1993). 
Though proven to be effective, insulin injections are not as sensitive as endogenous 
insulin and can result in unfavourable patient outcomes. In addition, patients can still 
have episodes of hypoglycemia, which can lead to unconsciousness, seizures, and brain 
damage. Additionally, multiple, daily injections can be a financial burden on the 
population.
An alternative to insulin injection regimens is whole pancreas or pancreatic islet 
transplantation (Ballinger and Lacy, 1972; Kelly et al., 1967; Shapiro et al., 2000). 
Transplantation is an option for therapy, as diabetes affects a single cell type. According 
to the Edmonton Protocol developed in 2000, 600,000 islet equivalents or 1 billion P-cells 
are required per transplant (Shapiro et al., 2000). The Edmonton Protocol built on these 
strategies to optimize islet transplantation in humans. This technique involves the 
transplantation of islets into the hepatic portal vein to allow them to lodge in a safe area.
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Patients undergoing transplantation require constant immunosuppression to prevent 
immune rejection. Unfortunately, longitudinal studies concluded that only 10% of 
patients were insulin independent 5 years following their initial transplant (Ryan et ah, 
2005). Approximately 80% of patients had islet graft survival at this point, however most 
demonstrated impaired function. This outcome has been postulated to be due to the 
inflammatory response that occurs immediately after transplantation, continued 
autoimmune destruction, in addition to the immunosuppressive drugs which are toxic to 
P-cells at high concentrations (Bell et ah, 2003; Moberg et al., 2002; Ryan et al., 2005). 
At the moment, the greatest limitation to this therapy is availability of donor tissues for 
transplantation. However, the Edmonton Protocol provides the proof-of-principle that 
cell based therapy can effectively restore insulin-independence in patients (Shapiro et al., 
2000).
1.2 Pancreatic Development
The mature pancreas is comprised of an exocrine compartment and an endocrine 
compartment (Figure 1.1). The exocrine compartment of the pancreas constitutes 98% of 
the total area and is made up of ductal and acinar cells that are responsible for secreting 
enzymes such as trypsinogen, chemotrypsin and pancreatic amylase to allow for digestion 
of carbohydrates, proteins and fatty acids (Rutter et ah, 1968). Conversely, the endocrine 
compartment of the pancreas constitutes 2% of the total area and is comprised of 
functional units called the islets of Langerhans. Once the pancreas is formed, it is limited
6
Figure 1.1 The pancreas is comprised of both exocrine and endocrine compartments
(A) The endocrine compartment of the pancreas is composed of structures termed the islets 
of Langerhans. These islets are comprised of 5 cell types, each of which secretes a specific 
endocrine hormone. The a-cell secretes glucagon, the P-cell secretes insulin, the 8-cell 
secretes somatostatin, the e-cell secretes ghrelin, and the PP cell secretes pancreatic 
polypeptide. Cells are aggregated around capillaries, which allow for the hormones to enter 
the vasculature and act on target tissues. (B) The exocrine compartment of the pancreas is 
composed of pancreatic acinar cells and ductal cells. Acinar cells secrete enzymes necessary
A
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in its ability to regenerate, as there is a restricted pool of progenitor cells that do not 
readily differentiate upon pancreatic cell loss (Stanger et al., 2007).
Pancreatic development begins at day 26 of human gestation when the definitive 
endoderm germ layer (DE), the layer that forms the embryonic gut and associated organs 
such as liver, lungs, and pancreas, evaginates into the surrounding mesenchyme, forming 
the dorsal pancreatic bud (Amit et al., 2000) (Figure 1.2). The ventral pancreatic bud 
arises from the caudal aspect of the hepatic/biliary bud by a similar mechanism six days 
later (Pictet et al., 1972). After both pancreatic buds have emerged, basal regions of each 
bud begin to elongate, forming stalks. Meanwhile, the apical region of each bud begins to 
branch at acute angles. Between day 37 and 42, the ventral and dorsal buds come into 
contact with each other due to gut rotation, resulting in the fusion of the ventral bud duct 
with the distal portion of the dorsal bud duct, forming the duct of Wirsung. The 
remaining portion of the dorsal bud duct is termed the duct of Santorini (Pictet et al., 
1972).
At day 40 to 60 of human gestation, or E13.0-14.0 in the mouse, there is a change 
in the cellular composition of the pancreas in what is known as the secondary transition. 
Prior to the secondary transition, the pancreas is comprised of predominantly immature a- 
cells (Pictet et al., 1972). During the secondary transition, there is a change in cell 
architecture due to expansion of endocrine cell numbers concurrent with exocrine acinar 
cell differentiation. The new endocrine cells assemble in a linear pattern along the ducts. 
Shortly after birth, the newly formed endocrine cells aggregate to form the islets of 
Langerhans (Pictet et al., 1972).
Figure 1.2: Schematic Representation of Pancreatic Development
(A) In humans, at 26 days of gestation, pancreatic buds are formed on both the dorsal and 
ventral aspect of the gut tube. (B) This occurs when the definitive endoderm evaginates 
into the surrounding mesenchyme. (C-D) Following bud formation, branching and 
elongation begins, with the dorsal bud forming a larger structure than the ventral bud. By 
day 42, the ventral and dorsal buds fuse due to gut rotation. (E) This fusion generates the 








1.2.1 Pancreatic Endocrine Cells
Within the islets of Langerhans, there are five endocrine cell types. The most 
predominant endocrine cell type, comprising 65-80% of the islets of Langerhans, is the P- 
cell (Pictet et al., 1972). In response to high blood glucose concentrations, glucose enters 
the p-cells through the GLUT2 glucose transporter and is metabolized to ATP. The 
resultant ATP induces p-cell membrane depolarization and insulin release. The insulin 
hormone then enters the circulation and eventually binds the insulin receptor on 
hepatocytes and myocytes, promoting the uptake of glucose, which is stored as glycogen 
in the liver and skeletal muscle. After insulin receptor binding, insulin is either released 
and able to act on other insulin receptors, or is degraded and cleared through the liver or 
kidney (Duckworth et al., 1998). P-cells also secrete C-peptide, a byproduct of insulin 
biosynthesis. To form mature insulin, proinsulin is cleaved by prohormone convertases 1 
and 2, excising C-peptide from the center of the proinsulin peptide. The resultant insulin 
peptide fragments are then joined by disulfide bonds, forming insulin (Steiner and Oyer, 
1967). In rodents, P-cells are localized to the center of the islets of Langerhans, while in 
humans, p-cells are dispersed randomly throughout the islets.
The second most predominant endocrine cell type in the adult pancreas is the 
glucagon-secreting a-cell, comprising between 10-15% of the endocrine compartment 
(Pictet et al., 1972). In response to low blood glucose, a-cells secrete glucagon, a peptide 
hormone that acts on hepatocytes to promote glycogenolysis. The resultant effect is 
increased blood glucose levels. In rodents, a-cells are localized to the outside of the 
islets, while in humans, a-cells are dispersed throughout the islets.
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The third most abundant endocrine cell type, comprising 3-10% of the pancreas is 
the 8-cell. Delta cells secrete the peptide hormone somatostatin. The role of somatostatin 
within the endocrine pancreas is to inhibit the release of insulin and glucagon. In rodents, 
8-cells are located at the periphery of the islet, while they are dispersed throughout in 
humans. Approximately 3-5% of the endocrine pancreas is comprised of PP cell that 
secrete pancreatic polypeptide. Pancreatic polypeptide (PP) is responsible for regulating 
hepatic glycogen levels by altering the insulin receptor found on the membrane of hepatic 
cells. In response to hypoglycemia, PP is released to promote glycogenolysis. Lastly, s- 
cells comprise less than 1% of the endocrine compartment of the pancreas. Epsilon cells 
are responsible for secreting ghrelin, a hormone responsible for stimulating the feeling of 
hunger by acting on the hypothalamus (Klok et al., 2007).
1.2.2 Growth Factor Signaling Pathways in Pancreatic Development
During pancreatic development, there are many signaling pathways that are 
required for proper organ patterning. Wnt signaling is an important, and temporally 
regulated process required for the formation of the pancreatic endoderm. Generally, 
Wnt3a is localized within the pancreatic mesenchyme, with overexpression leading to 
pancreatic hypoplasia affecting the islets of Langerhans, as well as pancreatic acinar cells 
(Heller et ah, 2002).
Mammalian transforming growth factor (TGF) -pi, -P2, and -P3 are detected in 
the developing pancreatic epithelium at E l2.5 in the mouse, and later co-localize within 
acinar cells (Crisera et ah, 1999). By E18.5, these TGF-P isoforms are specific to
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pancreatic ducts, concurrent with expression of TGF-|3 receptor type I and type II 
(Tulachan et al., 2007). Transgenic mice expressing TGF-pi under the rat insulin 
promoter have shown that TGF-(3 signaling is required for the ability of endocrine cells to 
form islets in the mouse pancreas (Lee et al., 1995; Sanvito et al., 1995). Inhibition of 
TGF-P signaling in mice through a dominant-negative form of TGF-P receptor type II 
results in ductal hyperplasia and acinar atypia (Bottinger et al., 1997). Taken together, 
TGF-P signaling is required to recruit duct cells to the endocrine lineage.
Activin signaling is required to specify definitive endoderm, as well as distinct 
stages throughout pancreatic development for proper patterning, but fine control of this 
pathway is essential. The notochord is a structure that forms during gastrulation and is 
responsible for patterning the axis of the developing embryo. The pancreas is situated 
adjacent to the notochord during development. In order for proper pancreas formation, 
sonic hedgehog (SHH) must be inhibited in the endoderm of the pancreatic region of the 
gut tube. The notochord secrets activins, which are inhibitors of SHH, resulting in areas 
of the gut tube that are capable of undergoing pancreatic bud formation (Hebrok et al., 
1998). In chick embryos, the removal of the notochord results in the absence of 
pancreatic gene expression (Kim et al., 1997; Melton et al., 1998). Activin A and B are 
expressed in developing rat and mouse pancreatic endocrine cells, especially a-cells 
(Furukawa et al., 1995; Maldonado et al., 2000). The addition of exogenous activin A to 
monolayer cultures of human fetal pancreas cells, results in increased number of insulin­
positive cells and subsequent increases in insulin content (Demeterco et al., 2000). 
Conversely, inhibition of activin by follistatin, which is found within the pancreatic
14
mesenchyme, results in exocrine differentiation (Miralles et al., 1998). These studies 
suggest that activin A is required for the differentiation of pancreatic endocrine cells.
Fibroblast growth factors (FGFs) play an important role in branching 
morphogenesis of the developing pancreas (Hogan, 1999). FGF10 expressed in the 
mesenchyme is required for proper pancreatic formation by controling mesenchymal-to- 
epithelial signaling. Mice lacking FGF10 have restricted pancreatic growth (Bhushan et 
al., 2001). Conversely, ectopic expression of FgflO in vivo under the control of the Pdxl 
promoter in mice results in increased proliferation of the pancreas at the expense of cell 
differentiation, as cells maintained a pancreatic progenitor phenotype and were unable to 
undergo terminal differentiation (Edlund et al., 2003). It is believed that FGF signaling in 
the pancreas is mediated by Notch signaling. This has been shown in studies where 
overexpresion of FGF 10 in transgenic mice results in the maintenance of Notch pathway 
activation, preventing pancreatic progenitor differentiation (Norgaard et al., 2003). In the 
pancreas, inhibition of Notch signaling results in robust commitment of cells to the 
endocrine lineage (Edlund et al., 1999).
1.3 Pancreatic Transcription Factors
1.3A  SOX17
Sry-related HMG box genes encode a family of transcription factors that possess a 
highly conserved high mobility group (HMG) responsible for DNA binding in the minor 
groove (Schepers et al., 2002; Wegner, 1999). This HMG box was originally identified in 
SRY, the sex determining gene on the Y chromosome. In general, SOX transcription
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factors have weak binding specificity in addition to low affinity for DNA (Wegner, 
1999). Sox transcription factors are encoded by 20 genes in human and mouse.
Sry-related HMG-box 17 (SOX17) is a 414aa transcription factor that plays a role 
in embryonic development and cell fate determination through the regulation of Wnt3a 
signaling (Figure 1.3 A). SOX17 is classified into the F group of SOX genes along with 
SOX7 and SOX 18, transcription factors that share similarity outside the DNA-binding 
domain (Dunn et al., 1995; Schepers et al., 2002; Taniguchi et al., 1999). Importantly, 
Soxl7  has been found to play an essential role in endoderm differentiation: it is expressed 
concurrent with DE formation and is downregulated upon DE specification (Kanai- 
Azuma et al., 2002). Soxl7  null mice are embryonic lethal, due to apoptosis of the 
foregut endoderm and failure of mid- and hindgut expansion. Using chimera assays, 
Soxl7  embryonic stem (ES) cells were shown to contribute to all aspects of gut DE, 
however they undergo incrased apoptosis in the foregut, and fail to differentiate in the 
posterior regions (Kanai-Azuma et al., 2002).
1.3.2 PDX1
Pancreatic and duodenal homeobox gene 1 (PDX1) is a 283aa transcription factor 
that regulates the expression of insulin, somatostatin, islet amyloid polypeptide, 
glucokinase, Glut2 as well as itself (Figure 1.3 B) (Hui and Perfetti, 2002). In mice and 
humans, all pancreatic endocrine and exocrine cells are derived from PDX1 positive 
progenitors (Gu et al., 2003). PDX1 is characterized by a central DNA binding 
homeodomain that possesss a signal for nuclear localization (Hessabi et al., 1999), Lu
Figure 1.3: Pancreatic Transcription Factor Structures
Schematic representation of pancreatic transcription factor structures. (A) SOX 17 has a 
SOX HMG box domain at the N-terminus of the transcription factor. (B) PDX1 contains 
a transactivation domain at the N-terminal of the protein, a homeodomain that includes a 
nuclear localization signal in the center of the protein, and a phosphorylation site at the C- 
terminus. (C) NGN3 belongs to the basic helix-loop-helix family of transcription factors 
that contain a helix-loop-helix domain in the center of the protein. (D) PAX4 has a paired 
box domain at the N-terminus of the protein, in addition to a homeodomain that is found 























1996). The N-terminus of PDX1 contains a transactivation domain that allows the protein 
to interact with other transcription factors and transcriptional co-regulators such as 
hepatocyte nuclear factor 6 (HNF6), SOX9, hepatocyte nuclear factor 1 homeobox B 
(HNF1P), and forkhead box A2 (FOXA2) (Mosley and Ozcan, 2004; Oliver-Krasinski et 
al., 2009). Additionally, there is a proline-rich domain situated in the middle of the 
protein that has been shown to be involved in heterodimerization with the DNA binding 
protein Pre B-cell leukemia transcription factor (PBX1) and varying additional binding 
partners to form a transcriptional regulatory complex (Goudet et al., 1999). The C- 
terminus of PDX1 is not essential for DNA binding, however it is necessary for the 
activation of target gene promoters either by direct interaction, or by changing the 
conformation of other interacting regions (Oliver-Krasinski et al., 2009; Peers et al., 
1994). There are many islet transcription factors such as Pax6, MafA and FoxA2 that 
bind to PDX1 and activate it through conserved cis-acting elements between 1923bp and 
2153bp. In addition, Pdxl binds to and regulates several promoters for downstream 
genes such as Nkx6.1 and Pax6 as well as preproinsulin (Svensson et al., 2007).
In the mouse, expression of Pdxl is restricted to the developing pancreas 
following pancreatic specification of the foregut endoderm. By E10.5, Pdxl expression is 
downregulated throughout the pancreatic compartment and remains low until E l3.0 when 
it is upregulated upon (3-cell differentiation (Ohlsson et al., 1993). Pdxl expression is 
maintained in adult P-cells (Ahlgren et al., 1998). Additionally, Pdxl is expressed in 
other tissues such as the skin (Mazur et al., 2010). Pdxl null mice, as well as mice 
homozygous for a targeted deletion of the homeodomain encoding exon 2 of the Pdxl 
gene lack a pancreas and consequently, die within a few days of birth (Ahlgren et al.,
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1996; Jonsson et al., 1994). Pdxl haploinsufficient mice have smaller islets that contain 
fewer (3-cells, leading to decreased insulin secretion and glucose intolerance that 
ultimately results in diabetes (Offield et al., 1996). In humans, a mutation at amino acid 
178, located within the second helix of the homeodomain, results in neonatal diabetes 
with subclinical exocrine deficiency (Nicolino et al., 2010), while a homozygous 
frameshift mutation at amino acid 63 prevents translation of the homeodomain as well as 
the C-terminus, thereby causing pancreatic agenesis (Stoffers et al., 1997). Individuals 
that are heterozygous for PDX1 mutations associated with neonatal diabetes will later 
develop maturity onset diabetes of the young 4 (MODY4) (Nicolino et al., 2010).
Given its function during pancreatic development, several studies have tested the 
ability of Pdxl expression to induce endocrine differentiation. Mouse ES cells with 
ectopic tet-inducible Pdxl gene expression have been differentiated following a 5 step 
pancreatic differentiation protocol. At the end of the differentiation process, these cells 
express somatostatin, insulin2, Nkx2.2, Pax4, Pax6 and Ngn3. Though these cells were c- 
peptide positive, they did not secrete insulin in response to glucose stimulation (Miyazaki 
et al., 2004). In contrast, rat small hepatocytes can successfully be differentiated into 
insulin-producing cells through overexpression of Pdxl by adenovirus transfection. 
These cells also expressed pancreatic markers Ngn3, Pax6, Nkx2.2 and Nkx6.1. 
Unfortunately, small hepatocytes, the progenitor cell type in the liver, are difficult to 
isolate from the liver, and functional analyses have not been performed on these cells 
(Kawasaki et al., 2008). Stable PDX1 overexpressing telomerase-immortalized bone 
marrow derived mesenchymal stromal cells have also been generated. These cells 
demonstrate pancreatic gene expression and insulin promoter activity. However, these
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cells were heterogeneous when stained for insulin and c-peptide, and did not respond to 
glucose at a biologically relevant level (Limbert et al., 2011).
1.3.3 NGN3
Neurogenin 3 (NGN3) is a 214aa basic helix loop helix transcription factor 
necessary for the development of hormone-producing islets (Figure 1.3C). In the 
developing mouse pancreas, Ngn3 expression is initiated at E8.5 in the dorsal pancreatic 
bud, while expression begins at E9.5 in the ventral pancreas. From E9.5 to E12.5, 
expression of Ngn3 is localized to the pancreatic endoderm where it is maintained until 
birth, and subsequently downregulated due to auto-repression (Gradwohl et al., 2000; 
Smith et al., 2004). In addition to pancreatic expression, Ngn3 is expressed in the 
developing and mature hippocampus (Simon-Areces et al., 2010), as well as neuronal 
progenitor cells from E9.0 to E14.0 (Lee et al., 2001; Sommer et al., 1996). Ngn3 
positive cells give rise to pancreatic endocrine cells that express endocrine transcription 
factors such as Nkx6.1 and Pax6 (Jensen et al., 2000; Smith et al., 2004). It has been 
found that Ngn3 binds to promoters of NeuroD, Pax4 and insulinoma associated antigen 1 
(Ia l) (Huang et al., 2000; Smith et al., 2003).
Mice lacking Ngn3 lack the endocrine component of the pancreas, leaving an 
exocrine compartment that contains few glucagon expressing cells. These mice develop 
diabetes due to a lack of P-cells and die between 1 and 3 days after birth (Gradwohl et al., 
2000). Ectopic expression of Ngn3 in pancreatic ductal cells in vivo using an adenovirus 
results in the expression of endocrine specific genes, however this starting population is 
limited (Gasa et al., 2004). Ectopic NGN3 expression in human pancreatic ductal cells
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produces insulin positive cells, however this occurs in only 13% of the cells (Heremans et 
al., 2002). In contrast, in ovo electroporation of Ngn3 in chick embryos results in 
glucagon and somatostatin producing cells, however no insulin or c-peptide positive cells 
were reported (Grapin-Botton et al., 2001). Ectopic expression of Ngn3 in conjuction 
with Pdxl in mouse ES cell-derived endoderm generates insulin and c-peptide positive 
cells, however these cells are not responsive to glucose (Kubo et al., 2011). 
Overexpression of Ngn3, MafA, and Pdxl is capable of transdifferentiating pancreatic 
acinar cells into insulin positive cells in vivo, however this strategy is only 20% efficient 
and has a limited starting population (Zhou et al., 2008).
1.3.4 PAX4
Paired box gene 4 (PAX4) is a 343aa nuclear transcription factor that is localized 
to the endocrine pancreas during embryonic development (Figure 1.3 D) (Sosa-Pineda et 
al., 1997). PAX genes encode regulators of embryonic organ development (Mansourie et 
al., 1996) and are characterized by a domain consisting of a highly conserved 128 amino 
acid motif that possesses DNA binding activities (Noll 1993). In particular, Pax4 and 
Pax6 share a homeodomain, as well as a highly conserved octapeptide (Dahl et al., 1997). 
Expression of Pax4 begins at E 10 in a small number of cells in the pancreatic bud (Sosa- 
Pineda et al., 1997). By E14.5, there is a significant increase in Pax4 positive cells in the 
dorsal pancreas, and by E15.5 the number of Pax4 expressing cells reaches its maximum 
(Dohrmann et al., 2000; Sosa-Pineda et al., 1997). Pax4 is not expressed in any exocrine 
cell type (Sander 1997, St Onge 1997). Pax4 is directly regulated by Ngn3, and serves to 
regulate expression of downstream targets including Nkx6.1 (Smith et al., 2003; Tang et
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al., 2006). It has been shown that Pax4 is required to maintain proliferation and survival 
of pancreatic P-cells (Brun et al., 2004).
At birth, Pax4 null mice have a normal pancreas with respect to size and weight; 
however, the pancreas lacks insulin-secreting (3- and somatostatin-secreting 5- cells. To 
compensate for the lack of P and 8 cells, there is an overabundance of a cells that are 
situated within the centre of an islet-like structure. Homozygous / >ax4-deficient mice die 
3-5 days after birth due to hyperglycemia (Sosa-Pineda et al., 1997). Overexpression of 
PAX4 in HESC following embryoid body-mediated definitive endoderm differentiation 
produces cells that exhibit functional properties that are typical of P-cells. These cells 
comprise 90% of the resultant cell population (Liew et al., 2008). Transgenic mice that 
express Pax4 in the pancreatic endocrine tissue, or pancreatic epithelium die between 3 
and 12 weeks after birth due to hyperglycemia. These mice had enlarged islets that 
contained mostly P-cells, as ectopic Pax4 expression converted a-cell progenitors to P- 
cell progenitors (Collombat et al., 2009).
1.3.5 Additional Pancreatic Transcription Factors
V-Maf musculoaponeurotic fibrosarcoma oncogene homolog A (MAFA) is a 
transcription factor required for functional glucose-stimulated insulin secretion in the 
pancreas (Kataoka et al., 2002). In the pancreas, Maf proteins function by interacting 
with other bZip proteins, which are transcription factors that contain basic leucine zipper 
domains, forming heterodimers (Igarashi et al., 1994) that bind to the RIPE3bl element in 
the promoter of genes such as insulin (Kataoka et al., 2002). During development,
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expression of MafA is restricted to developing insulin positive cells, and is responsible for 
tissue specific insulin expression (Matsuoka et al., 2004). MafA is initially detected at 
E l3.5 in mice, during the secondary transition of pancreatic development (Matsuoka et 
al., 2004). Conversely, MafB is present in developing a- and P-cells (Artner et al., 2006), 
but is restricted to a-cells following birth (Nishimuro 2006). In the development of the 
pancreatic p-cell, there is a transition between MafB expression and MafA expression that 
is required for proper glucose stimulated insulin secretion. Cells that are MafB positive 
and insulin positive are not functional until they are MafA positive and insulin positive 
(Kroon et al., 2008). MafA'1' mice have normal islet architecture at birth, however by 12 
weeks of age, there is a change in the composition of pancreatic islets with an increase the 
ratio of a- to P-cells. Consequently, MafA'1' mice develop overt diabetes mellitus (Zhang 
et al., 2005). Overexpression of MafA in conjunction with Pdxl and NeuroDl can induce 
the expression of endogenous insulin in the liver (Kaneto et al., 2005). Alternatively, 
overexpressing MafA concurrently with Pdxl and Ngn3 is capable of transdifferentiating 
pancreatic acinar cells into insulin positive cells (Zhou et al., 2008). In ovo 
electroporation of MafA in embryonic chick endoderm lead to the formation of insulin 
positive cells (Artner et al., 2008). Human placenta derived multipotent stem cells that 
overexpress MAFA were assessed by microarray analysis and were found to exhibit a 
gene expression profile consistent with pancreatic islets. Additionally, these cells were 
responsive to glucose and corrected hyperglycemia in immunocompromised mice that 
had streptozotocin-induced diabetes. A downfall to these cells is that they co-express 
glucagon and insulin (Chiou et al., 2011).
24
1.4 Human Embryonic Stem Cells
Human embryonic stem cells (HESC) are derived from the inner cell mass of the 
blastocyst, which is formed 4-5 days following fertilization. If maintained in the 
appropriate medium, containing basic fibroblast growth factor, HESC remain pluripotent 
and have the potential to form all 220 cell types of the body, including pancreatic P-cells 
(Thomson et al., 1998; Xu et al., 2005). Traditionally, HESC are cultured on mouse 
embryonic fibroblasts (MEFs) or in the presence of MEF-conditioned media. HESC have 
high levels of telomerase activity, allowing these cells to replicate indefinitely (Harley et 
al., 1992). HESC are characterized by the expression of the cell surface glycoproteins 
stage-specific embryonic antigen (SSEA)3 , SSEA4, TRA-1-60 and TRA-1-81, in 
addition to being alkaline phosphatase positive (Thomson et al., 1998). Additionally, 
given their pluripotent nature, HESC can produce cancerous and non-cancerous tumours 
called teratomas that contain tissues from each primary germ layer when injected into 
severe combined immunodeficient (SCID) mice.
Undifferentiated HESC have a distinct, unique morphology characterized by 
tightly packed colonies with no observable cell boundaries. The cells possess a high 
nuclear to cytoplasmic ratio with prominent nucleoli (Thomson et al., 1998). HESC are 
capable of spontaneous differentiation to all cell types, with first indication of HESC 
differentiation being change in cell morphology (Imreh et al., 2006).
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1.4.1 Differentiation Strategies to Generate (3-Cells from Human Embryonic Stem Cells
Several strategies have been developed for the generation of (3-cells from 
pluripotent HESC. Growth factor-mediated approaches have yielded stepwise protocols 
to generate a population of pancreatic-like cells (D'Amour et al., 2005; D'Amour et al., 
2006; Jiang et al., 2007a; Jiang et al., 2007b; Shim et al., 2007). Although these methods 
have been extensively characterized, they have limitations that are undesirable. 
Specification of DE using Activin A results in a heterogeneous, non-proliferative 
population of cells, thereby limiting the population that can further differentiate into 
pancreatic cell types. Additionally, these protocols produce a population of cells in which 
the (3-cell phenotype comprises less than 15% of the final population. Furthermore, 
transplantation of these (3-cells in mice does not generate functional cells in vivo, and the 
mice formed teratomas (D'Amour et al., 2005). Recent studies have optimized growth 
factor-mediated approaches by extending activin A treatment to specify DE, followed by 
inhibition of activin A, nodal, BMP and TGF-P following pancreatic progenitor formation 
in (3-cell development, however resultant populations contain only 25% C-peptide 
positive cells (Nostro et al., 2011). These limitations have given rise to a need for a 
method to generate a homogenous population of pancreatic endocrine precursors that 
maintain a replicative capacity enabling the cell expansion required for eventual cell- 
based therapies.
1.4.2 Transgenic Strategies fo r  Pancreatic Development from HESC
Pancreatic exocrine cells have been transdifferentiated into pancreatic endocrine 
cells by in vivo viral-mediated gene delivery of the transcription factors Mafa, Pdxl and
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Ngn3. The initial population of pancreatic exocrine cells is not self-renewable and the 
efficiency of transdifferentiation is very low (Zhou et al., 2008).
1.4.2 Genetic Manipulation o f Human Embryonic Stem Cells
1.4.2.1 ER12 System
T2The estrogen receptor ligand binding domain (ER ) has been used to 
to generate transgenes that are constitutively expressed but active only after the addition 
of 4-OH Tamoxifen to culture media (Hayashi and McMahon, 2002). This inducible 
construct allows for the control of the duration of transcription factor activity, which is 
beneficial when mimicking its developmental pattern of activity. The addition of 4-OH 
Tamoxifen allows the fusion protein to translocate into the nucleus, enabling it to bind 
DNA and regulate transcription (Figure 1.4).
1.4.2.2 piggyBac System
The piggyBac (PB) transposase system is a non-viral vector system that uses the 
transient expression of a transposase enzyme and two inverted terminal repeats flanking 
the gene of interest to insert transgenes into the host genome at any TTAA site (Figure 
1.5). This system is the most efficient transposon system characterized for use in 
mammalian cells and is unique in that transgenes can be removed leaving no genetic 
footprint behind using transient expression of PB transposase. The PB-TET system 
allows the gene of interest to be turned on/off by the addition/removal of doxycycline, 
which acts through the tet02 promoter. PB-TET is co-electroporated with the PB
Figure 1.4: ERT2 System for Inducible Gene Delivery
(A) The ERt2 system allows for a gene of interest, fused in frame to the estrogen receptor 
ligand binding domain (ERT2), to be constitutively expressed and held at the cytoplasmic 
membrane. (B) Following the addition of 4-OH Tamoxifen, an estrogen analog that 
shows a higher affinity for the mutated ERT2 receptor, the fusion protein translocates into
the nucleus where it can become active.

Figure 1.5 Transposon Based Tools for Inducible Transcription Factor Expression 
in HESC
(A) The tet02 piggyBac transposase system allows for the gene of interest (GOI), which 
is cloned into the PB-TET plasmid and flanked by inverted terminal repeats (ITR), to 
jump into the genome following transient expression of the piggyBac transposase 
enzyme. Entry occurs at TTAA sites and transgenic clonal populations selected for 
blasticidin resistance. (B) Transcription of the DNA of interest is induced by the addition 
of doxycycline to the culture media, which binds the reverse tetracycline transactivator 
(rtTA) protein, allowing it to bind the tet operator and initiate transcription. (Obtained by 
MTA from Dr. A. Nagy, Mount Sinai Hospital, Toronto). IRES -  Independent ribosomal 
entry site, Bgeo -  P-galactosidase/neomycin resistance fusion gene, polyA -  
polyadenylation tail, CAG -  CMV enhancer combined with chicken P-actin promoter, 





transposase plasmid containing the functional transposase enzyme that permits the 
integration of PB-TET and CAG-rtTA-blasticidin plasmids into the genome, which 
contains the reverse tetracycline transactivator necessary for transcription of the gene of 
interest. When bound by doxycycline, the rtTA protein acts on the tet02 promoter to 
drive transcription of the gene of interest (Cadinanos and Bradley, 2007; Ding et al., 
2005; Wang et al., 2008). Previous studies have used this method of gene delivery for the 
expression of c-Myc, Klf4, Sox2 and Oct4 in mouse fibroblasts and reported functional 
transcription factor activities (Woltjen et al., 2009).
1.5 Rationale
Diabetes is becoming increasingly prevalent in North America. Currently the only 
treatment options are insulin injection reginmens, or whole pancreas and pancreatic islet 
transplantation. Unfortunately, there is a scarce source of donor tissues for 
transplantation, as each transplant requires approximately 1 billion P-cells according to 
the Edmonton Protocol. This project will assay the ability of three independent 
transcription factors (PDX1, NGN3, PAX4) to specify a pancreatic endocrine phenotype 
following ectopic expression in HESC-derived definitive endoderm. Additionally, to 
better recapitulate the transient and/or biphasic patterns of transcription factor expression 
during development, cells with inducible, sequential activation of lineage-determining 
transcription factors will be generated to better recapitulate developmental patterns.
1.6 Hypothesis
Following SOX17-mediated definitive endoderm specification, expression of pancreas- 
specific transcription factors (PAX4, PDX1 or NGN3) will specify pancreatic endocrine 
progenitors from human embryonic stem cells.
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1.7 Objectives
The specific objectives of this research project are to:
1. Use constitutive SOX17 expressing HESC to screen for the ability of PAX4, 
PDX1 or NGN3 to specify pancreatic endocrine progenitors from definitive 
endoderm
2. Characterize definitive endoderm differentiation using transient activation of 
SOX17
3. Generate transgenic HESC for transient activation of SOX 17 to specify definitive 
endoderm, followed by PAX4, PDX1 or NGN3 to specify pancreatic endocrine 
cells
2.0 MATERIALS AND METHODS
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2.1 Cell Culture
CA1 and CA2 (O'Connor et al., 2008; Peerani et al., 2007), as well as CA2 pClip 
CAG-Fl-Pgeo-Fl-SOX 17-IRES-PURO (Seguin et al., 2008) and CA1 CAG-SOX17- 
ER^-PURO human embryonic stem cells (HESC) were maintained using conditions 
modified from established protocols for HESC derivation and culture (Thomson et al., 
1998). Briefly, cells were grown on mitotically inactivated mouse embryonic fibroblast 
feeders (SickKids ESC Facility) in knockout Dulbecco’s Modified Eagle Medium 
(DMEM) (Invitrogen) with 15% serum replacement, glutamax, penicillin/streptomycin, 
ImM nonessential amino acids, 0.5mM mercaptoethanol and lOng/mL FGF2. 
Transgenic cell populations were selected for by culturing in media supplemented with 
the appropriate antibiotic (0.6pg/mL puromycin, 1.0pg/mL G418). When cultures had 
attained 75% confluence, cells were passaged by enzymatic dissociation (0.05% Trypsin- 
EDTA), pelleted at 244 rcf/g for 3 minutes and split at a ratio of 1:9 (every 4-6 days).
2.2 Plasmid Construction
The open reading frame (ORF) corresponding to the human NGN3 gene was 
amplified by PCR from cDNA that was previously generated in our laboratory from 
HESC that were engineered to constitutively overexpress SOX 17 and underwent a 
pancreatic growth factor differentiation protocol, resulting in a population containing 
insulin-positive cells (Seguin et al., 2008). The sequence corresponding to the PAX4 
ORF was amplified by PCR from the full-length cDNA clone ID# HsCD00079789 
(Arizona State University). Both genes were amplified using primers designed to 
incorporate 5’Xhol and 3’Notl restriction enzyme sites to allow for directional cloning
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into the expression vector. The resultant amplicons were introduced into the pGEM-T 
vector by TA cloning. NGN3, and PAX4 ORFs were introduced independently into the 
CAG-MCS-IRES-NEO plasmid containing a CAG promoter (CMV enhancer combined 
with chicken [3-actin promoter), a multiple cloning site (MCS), an independent ribosomal 
entry site (IRES) and a neomycin-polyA cassette (Figure 2.1) (generously provided by 
Dr. H Niwa, RIKEN Center for Developmental Biology). This construct confers 
constitutive expression of the gene of interest in addition to a neomycin resistance gene. 
To confirm correct integration and gene sequence, the MCS of the resultant plasmid was 
sequenced.
A PB-TET-PDX1 plasmid was generated through a Gateway cloning LR reaction 
using lOOng of the mammalian gene collection full-length cDNA clone ID# 40080648 
(Invitrogen) PDXl-pDONR223.1, 150ng PB-TET plasmid, 5X LR Clonase II 
(Invitrogen), and TE buffer. Gateway cloning is a highly efficient method that uses site- 
specific recombination to move DNA sequences into vectors. The LR reaction allows a 
donor vector containing attL sites flanking the gene of interest to recombine with a 
destination vector containing attR sites flanking a ccdb sequence. The reaction mix was 
incubated at 37°C overnight and lpL transformed into 50pL of One Shot OmniMAX 2T1 
Phage-Resistant Cells (Invitrogen). Clonal populations were picked after ampicillin 
selection. Purified plasmids were sequence verified.
To visualize the activity of the PB-TET system, through green fluorescent protein 
(GFP), a PB-TET-GFP plasmid was obtained from Dr. Janet Rossant at the Hospital for
Sick Children.
Figure 2.1: Schematic representation of construction of plasmids for constitutive 
transcription factor expression in HESC
(A) The open reading frames (ORF) for NGN3 and PAX4 were amplified using primers 
designed to incorporate Xhol and Notl restriction sites for directional cloning. (B) The 
CAG-GFP-IRES-NEOR-PolyA plasmid was digested using Xhol and Notl to excise 
GFP. This plasmid contains a CAG promoter (CMV enhancer combined with chicken p- 
actin promoter), GFP (green fluorescent protein), 1RES (independent ribosomal entry 
site), NEOr (neomycin resistance gene), polyA (polyadenylated tail). (C) NGN3 and 
PAX4 ORFs were independently cloned into the CAG-IRES-NEOr plasmid. The 
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2.3 Generation of Transgenic HESC
To generate DE cells, CA2 HESC that contained a single integration of the pClip 
CAG-Fl-Pgeo-Fl-SOX17-IRES-PURO plasmid were used (Seguin et al., 2008). This 
plasmid contains a CAG promoter (CMV enhancer combined with chicken P-actin 
promoter), a floxed Pgeo element (P-galactosidase/neomycin resistance fusion protein), 
the SOX17 ORF, an independent ribosomal entry site (IRES), and the puromycin 
resistance gene. These cells remain undifferentiated in culture, and are induced to 
express SOX 17 following the introduction of Cre recombinase. The overexpression of 
SOX17 drives these HESC to a DE fate. To induce SOX17 expression, three confluent 
wells of a 6 well dish were enzymatically dissociated into single cells (0.05% Trypsin- 
EDTA) and centrifuged at 244 rcf/g for three minutes. The resultant cell pellet was 
resuspended in 400pL electroporation buffer (Gibco) and added to a 4mm electroporation 
cuvette containing 20pg of CAG-NLS-CRE plasmid. This plasmid contains a CAG 
promoter, a nuclear localization sequence (NLS) and the ORF for Cre recombinase. The 
electroporation cuvette was inserted into an electroporator (BioRad) and pulsed at 170V, 
1050pF. Cells were then plated into a 6 well plate, and after 48 hours, transgene 
expression was selected for using 0.6pg/mL puromycin.
HESC were previously generated in the lab that allow for control of dose and 
duration of SOX17 expression. CA1 HESC were electroporated with a CAG-SOX17- 
ER^-IRES-PURO plasmid. This plasmid contains a CAG promoter, the ORF for SOX 17 
fused in frame to the estrogen receptor ligand binding domain (ER ), an independent 
ribosomal entry site (IRES), and a puromycin resistance gene. This transgene is
39
constitutively expressed, but the SOX 17 transcription factor is only active following the 
addition of 4-OH Tamoxifen.
To generate HESC lines for pancreatic differentiation, NGN3, PAX4 or PDX1 
were introduced into both CA2 and CA2 CAG-SOX17-IRES-PURO HESC. To allow for 
stable integration of the CAG-NGN3-IRES-NEO or CAG-PAX4-IRES-NEO transgenes, 
these plasmids were linearized prior to electroporation. Plasmids were linearized by 
restriction enzyme digestion using Seal, which cuts once within the ampicillin resistance 
gene. Following digestion, the linearized plasmid was purified by ethanol precipitation, 
and resuspended in nuclease-free water to a concentration of 1 pg/pL.
HESC with constitutive expression of NGN3 or PAX4 were generated by 
electroporating CA2 or CA2 CAG-SOX17-IRES-PURO HESC with 20 pg of linearized 
plasmid. To generate HESC with constitutive expression of PDX1, cells were 
electroporated with 4 pg of each of PB-TET-PDX1, PB-Transposase, and CAG-rtTA- 
blasticidin. For electroporation, three wells of a 6 well dish of HESC were enzymatically 
dissociated into single cells (0.05% Trypsin-EDTA) and centrifuged at 244 ref/g for three 
minutes. The resultant cell pellet was resuspended in 400pL electroporation buffer and 
added to a 4mm electroporation cuvette containing the desired plasmid. The 
electroporation cuvette was inserted into an electroporator (BioRad) and pulsed at 170V, 
1050pF. Cells were then plated into a 6 well dish and after 48 hours, transgene 
expression was selected for using 0.8 pg/mL neomycin.
40
To induce the expression of PDX1, 500ng/mL doxycycline was added to media 
daily, 24 hours after electroporation. Following 48 hours of growth, cells were treated 
with neomycin (lpg/mL) to select for expression of the PB-TET-PDX1 transgene.
To generate PB-TET-GFP HESC, 3pg of PB-TET-GFP, 5pg PB Transposase, and 
5pg of CAG-rtTA-blasticidin plasmids were co-electroporated as described above into 
CA1 HESC. Cells were plated onto on Matrigel coated dishes (Invitrogen) in media that 
had been previously conditioned for 48 hours by mitotically inactivated mouse embryo 
fibroblast feeders (MEF-conditioned media). Matrigel was required because MEFs are 
not blasticidin resistant. After 48 hours, 5pg/mL blasticidin was added to culture media 
to select for expression of the CAG-rtTA-blasticidin plasmid. Clonal, blasticidin resistant 
colonies were picked each into one well of a four well dish on Matrigel in MEF 
conditioned media. Upon confluency, cells were enzymatically passaged 1:4 into four 
wells of a 12 well dish on Matrigel in MEF conditioned media. Once cultures were 
confluent, three wells were cryopreserved (90% FBS, 10% DMSO), and one well was 
expanded for experimental purposes. In total, 12 CA1 PB-TET-GFP clones were 
generated.
To generate CA1 CAG-SOXH-ER^-PURO PB-TET-PDX1 HESC, 3pg of PB- 
TET-PDX1, 3pg of PB Transposase, and 3pg of CAG-rtTA-blasticidin plasmids were 
introduced into SOX17-ER12 HESC by electroporation, as described above. After 48 
hours, 5pg/mL blasticidin was added to culture media to select for integration of the 
CAG-rtTA-blasticidin plasmid. Clonal blasticidin resistant colonies were picked each 
into one well of a four well dish on Matrigel in MEF conditioned media. Upon 
confluency, cells were enzymatically passaged 1:4 into four wells of a 12 well dish on
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Geltrex in MEF conditioned media. Once cells were confluent, three wells were 
cryopreserved (90% FBS, 10% DMSO), and one well was expanded for experimental 
purposes. In total, 30 clonal populations of CA1 CAG-SOX17-ERT2-PURO PB-TET- 
PDX1 HESC were generated.
2.4 Gene Expression Analysis
CA1 CAG-SOX17-ERT2-IRES-PURO HESC were plated into 12 well plates and 
treated with 0.1 p.M 4-OH Tamoxifen in the absence of FGF2 for either two hours, 24 
hours, two days, four days, or left untreated. At each timepoint, two wells of a 12 well 
dish were rinsed with PBS and 0.5mL Trizol Reagent © was added to each well. Cells 
were scraped and both wells were combined as one sample.
Following electroporation of CAG-NGN3-IRES-NEO, CAG-PAX4-IRES-NEO, 
or PB-TET-PDX1 into CA2 or CA2 pClip CAG-SOX17-IRES-PURO HESC, cells were 
maintained in HESC media with 1.0pg/mL G418. The day of electroporation was 
considered day 0. These cells were harvested at four days, eight days, 12 days, and 16 
days following electroporation. At each timepoint, two wells of a 6 well dish were rinsed 
with PBS and scraped in 0.5mL PBS. Both wells were pooled as one sample and 
centrifuged at 244 rcf/g for 3 minutes. The resultant cell pellet was resuspended in lmL 
Trizol Reagent ©.
Total RNA was isolated using Trizol Reagent © (Invitrogen) according to the 
manufacturer’s instructions and quantified by spectrophotometry on a Nanodrop 2000. 
To generate cDNA, lpg of RNA was reverse transcribed using the iScript cDNA
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synthesis kit (BioRad) according to the manufacturer’s instructions using reverse 
transcriptase and oligo(dT) and random primers. Gene expression was assessed by real­
time PCR using the BioRad CFX384. PCR reactions were run in triplicate using 40ng of 
cDNA per reaction and 400pM forward and reverse primers with 2X Sso Fast Eva Green 
reaction mix (BioRad) and 40 cycles of amplification (95°C 2 min; 95°C lOsec; 60°C 
30sec). Real-time PCR primers were designed to span intron-exon junctions, so that the 
PCR product from genomic DNA can be distinguished from the PCR product from cDNA 
through melt curve analysis. Primer sets were run on a standard curve to ensure an 
efficiency value between 90-110%. For every PCR experiment, specificity of primers 
was determined by performing a melt curve from 65°C to 95°C after each run. Gene 
expression was determined by relative quantification with values corrected for input using 
TATA-binding protein (TBP) and normalized relative to undifferentiated CA1 HESC. 
Analyses were performed in triplicate on three or four independent trials.
2.5 Immunostaining
Cells were fixed in 4% (w/vol) paraformaldehyde for 15 min at room temperature, 
rinsed twice in PBS, and stored at 4°C in PBS until use. For immunocytochemistry, cells 
were blocked for lhr in PBST (PBS, 0.1% Triton X -  100) with 5% fetal bovine serum 
(FBS). Antibodies for SOX17 (R&D AF1924) 1:100, OCT3/4 (sc-5279) 1:400, NANOG 
(ab80892) 1:400, and SSEA3 (mc-631) 1:10 were diluted in PBST with 5% FBS and 
primary antibodies were incubated for one hour. Cells were washed 2x10 min with 
PBST, followed by incubation with species specific secondary antibodies Alexa Fluor 
488 anti-goat IgG, anti-mouse IgG and anti-rabbit IgG 1:400 (Molecular Probes), and
43
Cy™5 anti-rat IgG 1:400 (Jackson ImmunoResearch) that were incubated for one hour at 
room temperature diluted in PBST with 5% FBS. Cells were washed 2x10 min with 
PBST, followed by nuclear staining using lpg/mL Hoechst 33258 in PBST for 10 min. 
Cells were washed 2x10 min with PBS, and stored in PBS for imaging. Fluorescence 
images were taken with a Zeiss Imager using a 10X objective, as well as a Leica DM6000 
inverted fluorescent microscope. Fluorescence imaging was performed on three 
independent trials.
2.6 LacZ Staining
To observe the functionality of CA1 SOX17-ERt2/PB-TET-PDX1 HESC through 
the expression of (3-galactosidase, which is downstream of PDX1, cells were treated with 
500ng/mL doxycycline for 4 days to induce the PB-TET-PDX1 transgene. Cells were 
then fixed in 0.25% glutaraldehyde for 15 min at room temperature, rinsed twice in PBS 
and covered in X-gal solution (0.2% X-gal, 2mM MgCl2 , 5mM K4Fe(CN)6*3H20, 5mM 
K3Fe(CN>6 in PBS) and incubated overnight at room temperature. X-gal solution was 
removed, cells were rinsed twice with PBS, covered with PBS and incubated until blue 
staining was visible. Staining was imaged on a Nikon SMZ-1500 stereoscope.
2.7 Statistical Analysis
Statistical analysis was performed using GraphPad Prism version 4.00. Real-time 
PCR quantification was examined using a one-way ANOVA and Dunnett’s post-test, as 




3.1 Constitutive expression of PAX4 in CA2 HESC does not change cell morphology.
To assess the ability of ectopic expression of PAX4 to specify pancreatic 
endocrine cells from pluripotent HESC, a transgene confering constitutive expression of 
pCAGS-PAX4-IRES NEO was introduced into CA2 HESC. Transgenic HESC were 
maintained as previously described and cells were imaged and RNA was isolated at 4, 8, 
12 and 16 day timepoints following electroporation. The day of electroporation was 
considered day 0. There was no observable change in cell morphology following 
constitutive expression of PAX4 in CA2 HESC during this time period (Figure 3.1 A). 
Real time PCR analysis of PAX4 gene expression was performed (Figure 3.1 B). 
Expression of the PAX4 transgene showed a trend towards decreased expression over 
time in the resultant transgenic cell populations.
3.2 Constitutive expression of PAX4 in DE cells does not change cell morphology.
To assess the ability of ectopic expression of PAX4 to specify pancreatic 
endocrine cells from definitive endoderm, pCAGS-PAX4-ERES NEO was introduced into 
SOX17 expressing HESC (DE). There was no change in morphology of DE cells in the 
presence of constitutive PAX4 expression (Figure 3.2 A). Real time PCR analysis of 
SOX17 and PAX4 gene expression was performed (Figure 3.2 B). Expression of both 
SOX 17 and PAX4 transgenes showed a trend towards decreased expression over time in 
the resultant transgenic cell populations. This finding is in keeping with the initial 
characterization of the SOX17 HESC lines (Seguin et al., 2008), which demonstrated 
decreased SOX17 expression with cell differentiation.
(A) Photomicrographs of replicate populations of CA2 PAX4 HESC imaged at 4, 8, 12 
and 16 day timepoints following electroporation. The day of electroporation was 
considered day 0. A transgene conferring constitutive expression of pCAGS-PAX4-IRES 
NEO was introduced into CA2 HESC (scale bars, 500 pm). There was no observable 
change in morphology following PAX4 expression in CA2 HESC. (B) Real time PCR 
quantification of PAX4 expresssion in resultant cell populations at 4, 8, 12 and 16 day 
time points. Values were corrected for input using the expression of TBP and expressed 
relative to undifferentiated HESC, (n=2). For PAX4, the SEM of technical replicates was 
not greater than 3.456.
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(A) Photomicrographs of replicate populations of SOX 17 PDX1 HESC imaged at 4, 8, 12 
and 16 day timepoints following electroporation. The day of electroporation was 
considered day 0. A transgene conferring constitutive expression of pCAGS-PAX4-IRES 
NEO was introduced into SOX17 expressing HESC (DE) (scale bars, 500 pm). There 
was no observable change in morphology following expression of PAX4 in DE cells. (B) 
Real time PCR quantification of PAX4 and SOX17 expression in resultant cell 
populations at 4, 8, 12 and 16 day time points. Values were corrected for input using the 
expression of TBP and expressed relative to undifferentiated HESC. Real time PCR 
analysis of SOX 17 and PAX4 gene expression showed a decreasing trend in both 
transgenic cell populations, (n=2). For PAX4, the SEM of technical replicates was not 
greater than 2.459. For SOX17, the SEM of technical replicates was not greater than
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3.3 Constitutive expression of PAX4 in CA2 HESC and DE cells does not change cell 
phenotype.
To assess the gene expression profiles of cells following constitutive expression of 
PAX4, real time PCR was performed. To assess changes to cell phenotype following 
transgene expression, cells were directly compared to HESC subjected to growth factor 
mediated differentiation using previously established protocols (D'Amour et al., 2006). 
We first assessed the expression of markers of DE including Cerberus 1 (CER1), C-X-C 
chemokine receptor type 4 (CXCR4), and distal-less homeobox 5 (DLX5) (Figure 3.3 A- 
C). In both CA2 HESC and DE cells, PAX4 overexpression resulted in a trend towards 
decreased CER1 and CXCR4 gene expression over 16 days of differentiation. However, 
DLX5 gene expression was increased at day 16 in SOX17 PAX4 HESC. We next 
examined the expression of markers of early pancreatic differentiation including PDX1 
and paired box gene 6 (PAX6). PDX1 and PAX6 showed decreased expression in both 
transgenic cell populations after 16 days of differentiation compared to unmodified CA1 
HESC (Figure 3.3 D-E). Next, markers of pancreatic progenitors NK2 homeobox 2 
(NKX2.2) and NK6 homeobox 1 (NKX6.1) were examined. There was no difference in 
NKX2.2 and NKX6.1 gene expression compared to unmodified CA1 HESC and growth- 
factor mediated pancreatic differentiation (Figure 3.3 G-H). To assess pancreatic 
hormone gene expression, we quantified mRNA levels of insulin (INS), glucagon (GCG) 
and somatostatin (SST) mRNA. Expression of INS showed a trend towards increased 
expression in both transgenic cell populations at day 12 and 16 compared to growth factor 
mediated pancreatic differentiation (Figure 3.3 I). Conversely, GCG and SST expression 
did not differ compared to unmodified CA1 HESC, levels below those detected in growth 
factor mediated pancreatic differentiation (Figure 3.3 J-K). Lastly, cytokeratin 19
Figure 3.3 Constitutive expression of PAX4 in CA2 HESC and DE cells does not 
change cell phenotype
Real time PCR quantification of gene expression in transgenic PAX4 populations at 4, 8, 
12 and 16 day time points following electroporation. The day of electroporation was 
considered day 0. Values were corrected for input using the expression of TBP and 
expressed relative to undifferentiated HESC. Data are presented as the mean ± SEM 
from duplicate experiments (n=2). (A-C) To assess DE differentiation, expression of 
CER1, CXCR4 and DLX5 was quantified. (D-F) To assess early pancreatic 
differentiation, expression of PAX6, PDX1 and NGN3 was quantified. (G-H) To assess 
pancreatic progenitor differentiation, expression of NKX2.2 and NKX6.1 was quantified. 
(I-K) Expression of pancreatic hormones INS, GCG and SST were quantified. (L-M) To 
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(CK19), and amylase (AMY) were investigated as markers of pancreatic ductal 
epithelium and exocrine differentiation respectively (Figure 3.3 L-M). Both transgenic 
cell populations had no change in CK19 expression compared to unmodified CA1 HESC 
until day 16 when SOX17 PAX4 HESC showed increased gene expression compared to 
CA2 PAX4 HESC and unmodified CA1 HESC (Figure 3.3 L-M). Throughout the 
timecourse, CK19 expression in these transgenic cell populations remained lower than in 
growth factor mediated pancreatic differentiation. AMY expression remained unchanged 
throughout the timecourse for both transgenic cell populations compared to unmodified 
CA1 HESC, while AMY gene expression was detected following growth factor mediated 
pancreatic differentiation. Taken together, these data suggest that overexpression of 
PAX4 does not promote pancreatic endocrine differentiation from HESC or DE.
3.4 Constitutive expression of PAX4 in CA2 HESC and DE cells does not result in 
mesodermal or ectodermal differentiation by day 16.
To determine if constitutive expression of PAX4 in HESC or DE cells resulted in 
differentiation to mesodermal or ectodermal lineages, selected marker genes were 
examined by real time PCR. To assess mesodermal differentiation, TEK tyrosine kinase 
(TIE2) and NK2 homeobox 5 (NKX2.5) were investigated (Figure 3.4 A-B). TIE2 gene 
expression was unchanged in both transgenic cell populations when compared to 
unmodified CA1 HESC. NKX2.5 gene expression decreased in both transgenic cell 
populations when compared to unmodified CA1 HESC. Next, SOX3 and NESTIN, 
markers of ectodermal differentiation were examined (Figure 3.4 C-D). There was no
Real time PCR quantification of gene expression in transgenic PAX4 populations at 4, 8, 
12 and 16 day time points following electroporation. The day of electroporation was 
considered day 0. Values were corrected for input using the expression of TBP and 
expressed relative to undifferentiated HESC. Data are presented as the mean ± SEM 
from duplicate experiments (n=2). (A-B) Expression of mesodermal markers TIE2 and 
NKX2.5 were quantified. (C-D) Expression of ectodermal markers SOX3 and NESTIN 
were quantified.
Figure 3.4 Constitutive expression of PAX4 in CA2 HESC and DE cells does not




















robust induction of either SOX3 or NESTIN gene expression observed when compared to 
unmodified CA1 HESC.
3.5 Constitutive expression of PDX1 in CA2 HESC results in cells with a flattened 
morphology after 16 days.
To assess the ability of PDX1 to specify pancreatic endocrine cells from 
pluripotent HESC, PB-TET-PDX1 was introduced into CA2 HESC. Transgenic HESC 
were maintained under standard conditions in media supplemented with 500ng/mL 
doxycycline to induce ectopic expression of PDX1. Cells were imaged and RNA was 
isolated at 4, 8, 12 and 16 day timepoints following electroporation (Figure 3.5 A). The 
day of electroporation was considered day 0. In transgenic populations A and B, cells 
adopted a more flattened morphology beginning at day 12, while transgenic population C 
adopted this morphology by day 16 (Figure 3.5 B). Real-time PCR analysis of PDX1 
gene expression was performed in the 3 seperate replicate populations (Figure 3.5 C). 
Although all 3 populations had significantly increased PDX1 expression at day 4 
compared to unmodified HESC, transgenic population C was shown to have the lowest 
amount of PDX1 transgene expression, demonstrating a 1402 fold increase vs HESC 
controls when compared to populations A and B which demonstrated relative expression 
values of 27071 fold and 24106 fold increase vs HESC controls respectively. However, 
PDX1 gene expression demonstrated a dramatic decrease over time in all three cell 
populations.
(A) Photomicrographs of replicate populations of CA2 PDX1 HESC imaged at 4, 8, 12 
and 16 day timepoints following electroporation. The day of electroporation was 
considered day 0. A transgene conferring constitutive expression of PDX1 was 
introduced into CA2 HESC (scale bars, 500 pm). Following 16 days of constitutive 
PDX1 expression, cells adopted a flattened morphology. (B) Photomicrographs of CA2 
PDX1 HESC at 4 days and 16 days demonstrating the flattened morphology of these cells 
at 16 days (scale bars, 500 pm). (C) Real time PCR quantification of PDX1 expresssion 
in resultant cell populations at 4, 8, 12 and 16 day time points. Values were corrected for 
input using the expression of TBP and expressed relative to undifferentiated HESC, 
(n=3). For PDX1, the SEM of technical replicates was not greater than 1.982.
Figure 3.5 Constitutive expression of PDX1 in CA2 HESC results in cells with a
flattened morpology after 16 days.
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3.6 Constitutive expression of PDX1 in DE cells does not change cell morphology.
To assess the ability of PDX1 to specify pancreatic endocrine cells from definitive 
endoderm, PB-TET-PDX1 was introduced into SOX17 expressing HESC (DE). 
Transgenic SOX17 HESC were maintained in media supplemented with 500ng/mL 
doxycycline to induce ectopic expression of PDX1. There was no change in cell 
morphology of DE cells in the presence of ectopic PDX1 expression (Figure 3.6 A). Real 
time PCR analysis of SOX17 and PDX1 gene expression was also performed (Figure 3.6 
B). SOX17 gene expression showed a decreasing trend in all transgenic cell populations. 
PDX1 gene expression varied substantially between the 3 replicate experiments and 
showed a trend of decreased expression over time in transgenic populations A and C.
3.7 Constitutive expression of PDX1 in DE cells results in insulin gene expression by 
day 16.
To assess gene expression profiles of cells engineered to constitutively express 
PDX1, we performed real time PCR. CER1, CXCR4, and DLX5 were once again 
examined as markers of DE (Figure 3.7A-C). There was no difference between CA2 
PDX1 HESC and SOX 17 PDX1 HESC at any of the timepoints examined. Markers of 
early pancreatic development including PAX4, PAX6 and NGN3 were also examined 
(Figure 3.7D-F). There were no differences in early pancreas gene expression in either 
transgenic cell population compared to unmodified CA1 HESC. Next, NKX2.2 and 
NKX6.1, markers of pancreatic progenitor differentiation, were assessed (Figure 3.7G-H). 
Following four days of ectopic PDX1 expression, both NKX2.2 and NKX6.1 expression 
showed a trend towards increased expression in SOX17 PDX1 HESC compared to CA2
Figure 3.6 Constitutive expression of PDX1 in DE cells does not change cell 
morphology.
(A) Photomicrographs of replicate populations of SOX 17 PDX1 HESC imaged at 4, 8, 12 
and 16 day timepoints following electroporation. The day of electroporation was 
considered day 0. A transgene conferring constitutive expression of PDX1 was 
introduced into DE cells (scale bars, 500 pm). (B) Real time PCR quantification of PDX1 
and SOX17 expresssion in resultant cell populations at 4, 8, 12 and 16 day time points. 
Values were corrected for input using the expression TBP and expressed relative to 
undifferentiated HESC (n=3). SOX 17 showed a trend towards decreasing gene
expression in all transgenic cell populations. PDX1 gene expression was variable 
between the 3 replicate experiments. For PDX1, the SEM was not greater than 1.592. 
For SOX17, the SEM was not greater than 0.912.
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Real time PCR quantification of gene expression in transgenic PAX4 populations at 4, 8, 
12 and 16 day time points following electroporation. The day of electroporation was 
considered day 0. Values were corrected for input using the expression of TBP and 
expressed relative to undifferentiated HESC. Data are presented as the mean ± SEM 
from triplicate experiments (n=3). (A-C) To assess DE differentiation, expression of 
CER1, CXCR4 and DLX5 was quantified. (D-F) To assess early pancreatic 
differentiation, expression of PAX4, PAX6 and NGN3 was quantified. (G-H) To assess 
pancreatic progenitor differentiation, expression of NKX2.2 and NKX6.1 was quantified. 
(I-K) Expression of pancreatic hormones INS, GCG and SST were quantified. (L-M) To 
assess exocrine differentiation, expression of CK19 and AMY was quantified, (n=3). 
Statistical analysis was performed in two ways with p<0.05 considered significant. 1) 
One way ANOVA with a Dunnett’s post hoc test to compare all time points to 
undifferentiated HESC. (* indicates significance from unmodified HESC) 2) Two-way 
ANOVA with a Bonferroni post hoc test to compare treatments within time points, (a 
indicats significance from CA2 PDX1 HESC, b indicates significance from growth factor 
mediated pancreatic differentiation, c indicates significance from SOX 17 PDX1 HESC).
Figure 3.7 Constitutive expression of PDX1 in DE cells results in insulin gene































PDX1 HESC and growth-factor mediated pancreatic differentiation. We then quantified 
expression of the pancreatic hormones INS, GCG and SST (Figure 3.7I-K). By day 16, 
INS gene expression in SOX17 PDX1 HESC was significantly increased compared to 
both CA2 PDX1 and growth factor mediated pancreatic differentiation, while GCG and 
SST gene expression did not differ between SOX17 PDX1 and CA2 PDX1 HESC. 
Lastly, CK19 and AMY, markers of ductal epithelium and exocrine pancreas were 
examined. There were no changes in exocrine gene expression in SOX 17 PDX1 and 
CA2 PDX1 HESC compared to unmodified CA1 HESC, however gene expression was 
lower than growth factor mediated pancreatic differentiation. Taken together, this data 
demonstrates that ectopic PDX1 expression in DE cells results in significantly increased 
insulin gene expression following 16 days of differentiation, however this is not 
accompanied by significant induction of any other markers of pancreatic endocrine 
differentiation examined.
3.8 Constitutive expression of PDX1 in CA2 HESC or DE cells does not result in 
mesodermal or ectodermal differentiation by day 16.
To determine if constitutive expression of PDX1 in HESC or DE cells resulted in 
differentiation to mesodermal or ectodermal lineages, selected marker genes were 
examined by real time PCR. To assess mesodermal differentiation, TIE2 and NKX2.5 
expression were investigated (Figure 3.8A-B). TIE2 gene expression was significantly 
increased in both transgenic cell populations at the 4 day timepoint when compared to
Real time PCR quantification of gene expression in transgenic PAX4 populations at 4, 8, 
12 and 16 day time points following electroporation. The day of electroporation was 
considered day 0. Values were corrected for input using the expression of TBP and 
expressed relative to undifferentiated HESC. Data are presented as the mean ± SEM 
from duplicate experiments (n=3). (A-B) Expression of mesodermal markers TIE2 and 
NKX2.5 were quantified. (C-D) Expression of ectodermal markers SOX3 and NESTIN 
were quantified, (n=3). Statistical analysis was performed in two ways with p<0.05 
considered significant. 1) One way ANOVA with a Dunnett’s post hoc test to compare 
all time points to undifferentiated HESC. (* indicates significance from unmodified 
HESC) 2) Two-way ANOVA with a Bonferroni post hoc test to compare treatments 
within time points (a indicats significance from CA2 PDX1 HESC, b indicates 
significance from growth factor mediated pancreatic differentiation, c indicates 
significance from SOX17 PDX1 HESC).
Figure 3.8 Constitutive expression of PDX1 in CA2 HESC or DE cells does not result
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unmodified CA1 HESC. NKX2.5 gene expression was not significantly altered from 
undifferentiated HESC. Next, NESTIN, a marker of ectodermal differentiation was 
examined (Figure 3.8C). NESTIN gene expression was significantly increased at 4 day 
timepoints in both transgenic populations compared to unmodified CA1 HESC. Taken 
together, these results suggest that at early timepoints, there is mixed differentiation with 
ectopic PDX1 expression in CA2 and DE cells, producing early stages of mesendodermal 
and neurectodermal differentiation, however by day 16, there is no observable change in 
mesodermal and ectodermal markers compared to unmodified CA1 HESC.
3.9 Constitutive expression of NGN3 in HESC does not alter cell morphology.
To assess the ability of ectopic expression of NGN3 to specify pancreatic 
endocrine cells from pluripotent HESC, a transgene conferring constitutive expression of 
pCAGS-NGN3-ERES NEO was introduced into CA2 HESC. Transgenic HESC were 
maintained under standard conditions in media supplemented with G418 to select for 
transgene expression for up to 16 days and cells were imaged and RNA was isolated at 4, 
8, 12 and 16 day timepoints following electroporation. The day of electroporation was 
considered day 0. There was no change in cell morphology in CA2 HESC in the presence 
of constitutive NGN3 expression (Figure 3.9 A). Real-time PCR analysis of NGN3 gene 
expression was performed in the 4 separate replicate populations (Figure 3.9 B). 
Transgenic population A and C had relative expression values of 436526 and 75701- fold 
increase vs unmodified HESC controls respectively at day 4, compared to population B 
and D which had lower NGN3 transgene expression at 1061 and 340- fold increase vs
unmodified HESC controls.
Figure 3.9 Constitutive expression of NGN3 in HESC does not alter cell morphology
(A) Photomicrographs of replicate populations of CA2 NGN3 HESC imaged imaged at 4, 
8, 12 and 16 day timepoints following electroporation. The day of electroporation was 
considered day 0. A transgene conferring constitutive expression of pCAGS-NGN3- 
IRES NEO was introduced into CA2 HESC (scale bars, 500 pm). There was no 
observable change in morphology following NGN3 expression in CA2 HESC. (B) Real 
time PCR quantification of NGN3 expresssion in resultant cell populations at 4, 8, 12 and 
16 day time points. Values were corrected for input using the expression of TBP and 
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3.10 Constitutive expression of NGN3 in DE ceils results in a flattened morphology 
and the presence of cytoplasmic vacuoles.
To assess the ability of NGN3 to specify pancreatic endocrine cells from cells 
already committed to the definitive endoderm lineage, the constitutive pCAGS-NGN3- 
IRES-NEO transgene was introduced into HESC constitutively expressing SOX17 (DE 
cells). As described above, transgenic HESC were maintained for up to 16 days and cells 
were imaged at 4, 8, 12 and 16 day timepoints following electroporation (Figure 3.10 A). 
The day of electroporation was considered day 0. Following 4 days of NGN3 expression, 
there was no detectable change in cell morphology when compared to DE cells. At day 
eight, cells began to appear more flattened and small vacuoles were observed within the 
cytoplasm. Throughout the rest of the timecourse, cells maintained this altered flattened 
morphology and spread out, with some cells maintaining the presence of vacuoles at day 
16 (Figure 3.10 B). Real-time PCR analysis of SOX17 and NGN3 was performed in the 4 
separate replicate populations (Figure 3.10 C). Population A had the highest NGN3 
transgene expression with a relative expression value of 11565 fold compared to 
unmodified HESC controls. Population B had 892-fold NGN3 expression, while 
population C had 1482-fold expression and population D had 219 fold NGN3 expression 
compared to unmodified HESC controls. Additionally, each transgenic population 
showed a decreasing trend of SOX17 expression over 16 days.
Figure 3.10 Constitutive expression of NGN3 in DE cells results in a flattened 
morphology and the presence of cytoplasmic vacuoles.
(A) Photomicrographs of replicate populations of CA2 NGN3 HESC imaged at 4, 8, 12 
and 16 day timepoints following electroporation. The day of electroporation was 
considered day 0. A transgene conferring constitutive expression of NGN3 was 
introduced into CA2 HESC (scale bars, 500 pm). Following 8 days of NGN3 expression, 
cells adopted a flattened morphology with the presence of cytoplasmid vacuoles, with this 
morphology being maintained over the duration of the timecourse. (B) Photomicrographs 
of SOX 17 NGN3 HESC at 4 days and 16 days demonstrating the flattened morphology 
and cytoplasmic vacuoles within these cells at day 16 (scale bars, 500 pm). (C) Real time 
PCR quantification of NGN3 and SOX17 expresssion in resultant cell populations at 4, 8, 
12 and 16 day time points. Values were corrected for input using the expression of TBP 
and expressed relative to undifferentiated HESC, (n=4). SOX 17 showed a trend towards 
decreased gene expression in all transgenic populations. NGN3 demonstrated variable 
gene expression between replicate populations. For NGN3, the SEM was not greater than 
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3.11 Constitutive expression of SOX17 and NGN3 in HESC drives cells to a 
pancreatic endocrine fate.
To assess the gene expression profiles of cells that constitutively expressed 
NGN3, we performed real time PCR. To assess the efficiency of differentiation, cells 
were directly compared to HESC subjected to growth factor mediated differentiation 
using previously established protocols (D'Amour et al., 2006). We first assessed the 
expression of markers of DE including CER1, CXCR4, and DLX5 (Figure 3.11 A-C). In 
both CA2 HESC and DE cells, NGN3 overexpression results in a trend towards decreased 
DE gene expression by 16 days of differentiation. We next examined the expression of 
markers of early pancreatic differentiation including PAX4, PAX6 and PDX1. By day 
12, PAX4 expression is increased in cells that contain both SOX 17 and NGN3 
transgenes, in comparison to CA2 NGN3 HESC and growth-factor mediated pancreatic 
differentiation (Figure 3.11 D). Additionally, PAX6 expression was increased in both 
transgenic cell lines by day 16 compared to growth-factor mediated pancreatic 
differentiation (Figure 3.11 E). At day 8 and 12, PDX1 gene expression shows a trend 
towards increased gene expression in SOX17 NGN3 HESC compared to both CA2 
NGN3 HESC in addition to growth-factor mediated pancreatic differentiation (Figure
3.11 F). Next, markers of pancreatic progenitors NK2 homeobox 2 (NKX2.2) and NK6 
homeobox 1 (NKX6.1) were examined. At eight days of differentiation, NKX2.2 gene 
expression was increased in SOX 17 NGN3 HESC in comparison to both CA2 NGN3 
HESC and growth-factor mediated pancreatic differentiation (Figure 3.11 G). 
Additionally, NKX6.1 gene expression was significantly increased in SOX17 NGN3 
HESC at day 12 in comparison to CA2 NGN3 HESC, growth-factor mediated pancreatic 
differentiation, and unmodified HESC controls (Figure 3.11 H).
Figure 3.11 Constitutive expression of SOX17 and NGN3 in HESC drives cells to a 
pancreatic endocrine fate.
Real time PCR quantification of gene expression in transgenic NGN3 populations at 4, 8, 
12 and 16 day time points following electroporation. The day of electroporation was 
considered day 0. Values were corrected for input using the expression of TBP and 
expressed relative to undifferentiated HESC. Data are presented as the mean ± SEM 
from quadruplicate experiments (n=4). (A-C) To assess DE differentiation, expression of 
CER1, CXCR4 and DLX5 was quantified. (D-F) To assess early pancreatic 
differentiation, expression of PAX4, PAX6 and PDX1 was quantified. (G-H) To assess 
pancreatic progenitor differentiation, expression of NKX2.2 and NKX6.1 was quantified. 
(I-K) Expression of pancreatic hormones INS, GCG and SST were quantified. (L-M) To 
assess exocrine differentiation, expression of CK19 and AMY was quantified. Statistical 
analysis was performed in two ways with p<0.05 considered significant. 1) One way 
ANOVA with a Dunnett’s post hoc test to compare all time points to undifferentiated 
HESC (* indicates significance from unmodified HESC). 2) Two-way ANOVA with a 
Bonferroni post hoc test to compare treatments within time points, (a indicats significance 
from CA2 NGN3 HESC, b indicates significance from growth factor mediated pancreatic 
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To assess pancreatic hormone gene expression, we quantified mRNA levels of 
INS, GCG and SST. Expression of INS was significantly increased in CA2 NGN3 HESC 
at day 12 compared to unmodified HESC controls, while SOX 17 NGN3 HESC showed a 
trend towards increased INS gene expression throughout the timecouse (Figure 3.11 I). 
Conversely, GCG and SST expression did not differ compared to growth factor mediated 
pancreatic differentiation in both cell types until day 16, when CA2 NGN3 HESC had 
significantly increased SST compared to unmodified HESC controls (Figure 3.11 J-K). 
Lastly, cytokeratin 19 (CK19), and amylase (AMY) were investigated as markers of 
pancreatic ductal epithelium and exocrine differentiation respectively (Figure 3.11 L-M). 
In both transgenic cell populations, there was no change in ductal or exocrine gene 
expression, however they had lower gene expression compared to growth factor mediated 
pancreatic differentiation. Taken together, overexpression of NGN3 in DE cells suggests 
differentiation towards pancreatic endocrine progenitors.
3.12 Constitutive expression of NGN3 in CA2 HESC and DE cells does not result in 
mesodermal or ectodermal differentiation.
To examine the specificity of NGN3-induced differentiation in CA2 HESC and 
DE cells, we examined the expression of markers of both the mesodermal and ectodermal 
lineages. To assess mesodermal differentiation, TIE2 and NKX2.5 were investigated 
(Figure 3.12 A-B). At day 4, TIE2 was significantly upregulated in CA2 NGN3 HESC, 
however by day 16, there was no robust induction of mesodermal gene expression 
compared to unmodified CA1 HESC. Secondly, to investigate ectodermal gene 
expression, we determined the levels of SOX3 and NESTIN (Figure 3.12 C-D). No
Figure 3.12 Constitutive expression of NGN3 in CA2 HESC and DE cells does not 
result in mesodermal or ectodermal differentiation.
Real time PCR quantification of gene expression in transgenic PAX4 populations at 4, 8, 
12 and 16 day time points following electroporation. The day of electroporation was 
considered day 0. Values were corrected for input using the expression o f TBP and 
expressed relative to undifferentiated HESC. Data are presented as the mean ± SEM 
from quadruplicate experiments (n=4). (A-B) Expression of mesodermal markers TIE2 
and NKX2.5 were quantified. (C-D) Expression of ectodermal markers SOX3 and 
NESTIN were quantified. Statistical analysis was performed in two ways with p<0.05 
considered significant. 1) One way ANOVA with a Dunnett’s post hoc test to compare 
all time points to undifferentiated HESC (* indicates significance from unmodified 
HESC). 2) Two-way ANOVA with a Bonferroni post hoc test to compare treatments 
within time points. (a indicats significance from CA2 NGN3 HESC, b indicates 
significance from growth factor mediated pancreatic differentiation, c indicates 
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significant induction of either NESTIN or SOX3 gene expression was induced by ectopic 
NGN3 expression in either transgenic cell population relative to unmodified CA1 HESC. 
Taken together, these findings suggest that constitutive expression of NGN3 in CA2 
HESC and DE cells does not promote mesodermal or ectodermal differentiation.
3.13 Characterization of DE differentiation using inducible SOX17 activation in 
HESC
3.13.1 4-OH Tamoxifen regulates SOX17 transgene cytoplasmic location.
During development, SOX 17 is expressed during DE formation, and 
downregulated following formation of the gut tube (Kanai-Azuma et al., 2002). In order 
to better recapitulate this developmental pattern of transient expression, clonal HESC cell 
lines expressing a transgene conferring inducible activation of the SOX 17 transcription 
factor were previously generated in the Séguin lab. The SOX17 coding sequence was 
fused in frame to the estrogen receptor ligand binding domain (ER ) to generate a 
protein that is constitutively expressed but active only following the addition of 0.1 pM 4- 
OH Tamoxifen to culture media (Hayashi and McMahon, 2002). This inducible construct 
permits control of the duration of transcription factor activity, which is imperative when 
developing a differentiation strategy aimed at mimicking the developmental pattern of 
transcription factor activity. To visualize SOX 17 localization, immunocytochemistry was 
performed on SOX17-ER17 HESC that were either untreated (maintained under standard 
culture conditions), or treated with 0.1 pM 4-OH Tamoxifen for 2 hours, 24 hours, 2 days
Figure 3.13.1 4-OH Tamoxifen regulates SOX17 transgene cytoplasmic location.
Immunocytochemistry demonstrating cellular localization of SOX17. SOX17-ERT2- 
PURO HESC were treated with 0.1 pM 4-OH Tamoxifen for 2 hours, 24 hours, 2 days, 4 
days, or left untreated. Cells were analyzed by standard immunocytochemistry protocols 
using a polyclonal antibody for SOX17. SOX17 is restricted to the cytoplasm until the 
addition of 4-OH Tamoxifen, when it undergoes nuclear translocation within 2 hours,
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or four days (Figure 3.13.1). Immunolocalization of SOX17 demonstrated that SOX17-
rV/m%
ER was restricted to the cytoplasm prior to 4-OH Tamoxifen addition, however nuclear 
translocation is detected within 2 hours of 4-OH Tamoxifen addition, a cellular 
localization that is maintained in the continued presence of 4-OH Tamoxifen up to 4 days.
3.13.2 HESC adopt a DE phenotype following 4 days ofSOX17 activation.
To determine the duration of SOX 17 activation required to induce DE 
differentiation, CA1 SOX17-ERT2 HESC were treated with 4-OH Tamoxifen for up to 4 
days. Gene expression was quantified by real-time PCR with values corrected for TBP 
and normalized to unmodified CA1 HESC. Gene expression was compared to SOX 17- 
ER HESC cultured in media without bFGF to compare transcription factor mediated 
differentiation to spontaneous differentiation. Genes investigated were, CER1, CXCR4, 
DLX5 (definitive endoderm), GATA4, GATA6, HNF4a (pan-endoderm), and OCT4, 
NANOG (pluripotency) using previously validated primer sets. DE markers were 
upregulated within 24 hours, and significantly expressed by 4 days of 4-OH Tamoxifen 
exposure (Figure 3.13.2A). The pan-endoderm markers GATA4 and GATA6 were 
significantly increased following 4 days of 4-OH Tamoxifen treatment (Figure 3.13.2B). 
The expression of pluripotency markers remain unchanged throughout the timecourse 
(Figure 3.13.2C), findings in keeping with the previous characterization of the 
constitutive SOX17 expressing HESC which maintain OCT4 and NANOG expression 
despite their DE phenotype (Seguin et al., 2008). Taken together, these data suggest that 
cells adopt a definitive endoderm phenotype following 4 days of SOX17 activation.
Figure 3.13.2 HESC adopt a DE phenotype following 4 days of SOX17 
overexpression
(A) Schematic representation of the SOX17-ERT2-PURO transgene used for SOX 17 
delivery. (B-D) SYBR-based RT-PCR analysis of gene expression in SOX17-ER12 
HESC treated with 4-OH Tamoxifen for 2 hours, 24 hours, 2 days or 4 days. Expression 
of DE markers, pluripotency markers, and pan-endoderm markers suggests the robust 
induction of DE differentiation within 4 days. Gene expression normalized to TBP and 
expressed relative to untreated CA1 HESC (n=3). Furthermore, gene expression was 
compared to SOX17-ER12 HESC cultured in media without bFGF to compare 
transcription factor mediated differentiation to spontaneous differentiation. Statistical 
analysis was performed using a one way ANOVA with a Dunnett’s post hoc test to 
compare all time points to undifferentiated HESC. P<0.05 was considered significant (* 
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3.14 Characterization of an inducible system for second transgene delivery.
3.14.1 The piggyBac system is induced in HESC by doses o f doxycycline lOOng/mL or 
greater.
CA1 HESC were co-electroporated with a PB-TET-GFP plasmid (generated by J 
Rossant, SickKids), PB transposase plasmid, and PB-rtTA-blasticidin to generate novel 
clonal transgenic cell lines with doxycycline inducible GFP expression. To determine the 
dose of doxycycline required to induce transgene expression, two independent clonal cell 
lines were treated with increasing doses of doxycycline and imaged for GFP fluorescence 
up to 24hrs after doxycycline addition (Figure 3.14.1). The GFP transgene was induced 
by concentrations of doxycycline between lOOng/mL and lOOOng/mL, with no 
fluorescence detected at doses below lOOng/mL. Detection of fluorescence began 24 
hours after the addition of doxycycline at concentrations of doxycycline at lOOng/mL or 
greater.
3.14.2 The piggyBac system is maximally induced by 500ng/mL doxycycline.
To verify our fluorescence findings quantitatively, PB-TET-GFP cells were 
exposed to the same concentrations of doxycycline for 24 hours prior to harvesting for 
RNA extraction for real-time PCR. The expression of GFP was examined. In PB-TET- 
GFP clone D, GFP was found to increase approximately 50 fold when treated with 
lOOng/mL doxycycline and approximately 104 fold when treated with lOOOng/mL and 
500ng/mL doxycycline (Figure 3.14.2A). In PB-TET-GFP clone E, GFP increased
Figure 3.14.1 The piggyBac system is induced by doses of doxycycline lOOng/mL or 
greater
Fluorescence imaging of PB-TET-GFP HESC treated with increasing doses of 
doxycycline and imaged over 24 hours. Novel transgenic CA1 HESC containing the PB- 
TET-GFP transgene were subjected to increasing doses of doxycycline to visualize the 
activity of the PB-TET system in HESC. Tet-induced GFP expression was detected at 
concentrations of doxycycline lOOng/mL or greater, with detection beginning following 
24hrs of doxycycline treatment (n=l), scale bars lOOpM.
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SYBR-based RT-PCR analysis of PB-TET-GFP cells. Two clonal populations of PB-
TET-GFP HESC were treated with increasing concentrations of doxycycline for 24 hours 
to induce GFP expression. GFP is detected at doses lOOng/mL or greater, with maximal 
GFP at a dose of 500ng/mL. The amount of GFP was determined by absolute 
quantification (n=2).
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approximately 50 fold when treated with lOOng/mL doxycycline and approximately 103 
fold when treated with lOOOng/mL and 500ng/mL doxycycline (Figure 3.14.2B). For 
both clones, there was little detectable GFP induction at doses below lOOng/mL
3.14.3 The piggyBac system turns off following the removal o f doxycycline.
To ensure that transgene expression was reversable, doxycycline was removed 
from the culture media after 24 hours and cells were imaged for an additional 72 hours 
(Figure 3.14.3). The levels of GFP remained consistent at all doses of doxycycline until 
48 hours after removal when the levels of GFP showed a marked decrease.
3.14.4 The dose o f doxycycline used fo r  piggyBac induction (500ng/mL) does not affect 
HESC phenotype.
To ensure that the dose of doxycycline used to induce the PB system did not alter 
the HESC phenotype, PB-TET-GFP HESC, cells were treated with 500ng/mL 
doxycycline for 24 hours, and immunocytochemistry was performed to examine levels of 
OCT 4, NANOG and SSEA3 as markers of pluripotency (Figure 3.14.4A). Following 24 
hours of doxycycline treatment, there was no detectable change in the expression of these 
markers when compared to untreated HESC. To verify these findings quantitatively, four 
additional HESC lines were treated with 500ng/mL doxycycline for either 24 hours or 
four days and the expression of OCT4, NANOG and SOX2 was quantified by real-time 
PCR (Figure 3.14.4B). Following both 24 hour and four day doxycycline treatment, there
Fluorescence imaging of PB-TET-GFP HESC exposed to increasing doses of doxycycline 
and imaged up to 72 hours following doxycycline removal. After 48hrs, levels of GFP 
decreased demonstrating that the system had been turned off, (n=l), scale bars lOOpM.
Figure 3.14.3 The piggyBac system turns off following the removal of doxycycline
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Figure 3.14.4 The dose of doxycycline used for piggyBac induction (500ng/mL) does 
not affect HESC phenotype
(A) Immunocytochemistry of PB-TET-GFP HESC exposed to 500ng/mL doxycycline for 
24 hours express pluripotency markers OCT 3/4, NANOG and SSEA3 (n=4), scale bars 
200pM. (B) SYBR-based RT-PCR analysis of gene expression in 4 pluripotent cell lines 
treated with 0 and 500ng/mL doxycycline. Gene expression was normalized to TBP and 
expressed relative to untreated CA1 HESC. There was no significant difference in OCT4, 
NANOG or SOX2 gene expression between HESC treated with doxycycline and 
untreated CA1 HESC (n=4, p>0.05).
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was no significant difference between treated and untreated HESC for the expression of 
markers of the pluripotent state. We therefore concluded that the dose of doxycycline 
used in these studies, 500ng/mL, does not alter the HESC phenotype.
3.15 Characterization of double transgenic HESC with inducible SOX17 and PDX1.
Following the characterization of cells that allow for inducible SOX 17 activity, 
we required a second inducible system to deliver pancreatic transcription factor 
expression and further differentiate cells to pancreatic endocrine progenitors. Having 
established the efficacy of the piggyBac system in HESC, we proceeded with the 
introduction of PDX1 into SOX17-ER ER r2 HESC. The presence of the PB-TET-PDX1 
plasmid was verified by both LacZ staining and genomic PCR following doxycycline 
induction (Figure 3.15A-B). Preliminary characterization of clonal cell lines was 
performed by treating HESC with either 4-OH Tamoxifen or doxycycline for two days. 
Gene expression was assayed for SOX 17 and PDX1 in each clone, and compared to gene 
expression levels in human fetal pancreas RNA (obtained commercially from Invitrogen) 
(Figure 3.15C). Two clones were identified that had SOX17 gene expression and PDX1 
gene expression higher than in human fetal pancreas.
Figure 3.15 Characterization of double transgenic HESC with inducible SOX17 and 
PDX1
(A) P-galactosidase staining in clonal populations (W, CC, C, R) of CA1 SOX17-ER12 
PB-TET-PDX1 HESC after 2 days of doxycycline treatment (500ng/mL). P-galactosidase 
is expressed from the IRES-Pgeo portion of the PB-TET expression construct. Positive 
staining indicates that the PB-TET plasmid has integrated into the genome and is being 
actively expressed. (B) Genotyping of genomic DNA extractions from double transgenic 
cell lines confirms the presence of the Pgeo element. (C) SYBR-based RT-PCR analysis 
of a representative double transgenic cell line used to quantify expression levels of PDX1. 
Cells were untreated (U/T), or treated with either 0.1 pM Tamoxifen (TAM) or 500ng/mL 
doxycycline (DOX), or both for 2 days. Gene expression normalized to TBP, expressed 
relative to CA1 HESC and compared to levels in human fetal pancreas (HFP).
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4.1 Summary of Results
Pluripotent HESC are capable of differentiation into all 220 cell types present in 
the human body, providing tremendous potential for application in cell-based therapies. 
Diabetes mellitus is becoming increasingly prevalent in North America, highlighting the 
necessity to create a renewable source of pancreatic (3-cells for therapeutic purposes. To 
date, differentiation strategies to generate pancreatic endocrine cells from various starting 
cell populations including HESC, pancreatic exocrine cells, and pancreatic ductal cells 
have generated small clusters of non-proliferative endocrine cells, of which only a small 
proportion are functional (Bernardo et al., 2009; Blyszczuk et al., 2003; Collombat et al., 
2009; D'Amour et ah, 2006; Heremans et ah, 2002; Jiang et ah, 2007a; Jiang et ah, 
2007b; Kawasaki et ah, 2008; Kroon et ah, 2008; Kubo et ah, 2011; Lavon et ah, 2006; 
Liew et ah, 2008; Lin et ah, 2007; Minami et ah, 2005; Miyazaki et ah, 2004; Nostro et 
ah, 2011; Serafimidis et ah, 2008; Shim et ah, 2007; Thorel et ah, 2010; Zhou et ah, 
2008). Therefore, there is a need to develop alternate strategies by which pancreatic 
endocrine cells can be obtained to satisfy the large number of cells required to restore 
insulin secretion in response to physiological stimuli as per the Edmonton Protocol 
(Shapiro et ah, 2000).
The current study was undertaken to explore the hypothesis that ectopic 
expression of lineage-determining transcription factors could be used to generate a source 
of proliferative, homogenous pancreatic progenitor cells capable of subsequent 
differentiation to functional endocrine cell types, including (3-cells. Recent studies have 
shown that functional hepatocytes can be generated using inducible expression of SOX17, 
HEX and HNF4a, proving that transcription factor mediated differentiation is a viable
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and successful differentiation strategy (Takayama et al., 2011). To address our 
hypothesis, transgenic cell lines were generated from both HESC and definitive endoderm 
cells (SOX17) that constitutively expressed the pancreatic transcription factors PAX4, 
PDX1 or NGN3. Populations were analyzed for gene expression and compared to 
standard growth factor-mediated protocols for HESC pancreatic differentiation. Given 
the ability of transcription factor expression to drive HESC differentiation, this strategy 
was further elaborated using transgenic strategies to confer inducible gene expression in 
HESC thereby better recapitulating the patterns of expression seen during embryonic 
development. As such, HESC with inducible activity of SOX17, as well as transgenic 
HESC with inducible activity of both SOX17 and PDX1 were generated and 
characterized.
We present evidence that ectopic expression of PAX4 is not sufficient to specify 
pancreatic cells from HESC or DE. PDX1 expression in DE promoted the expression of 
insulin, however did not induce the expression of any additional markers of endocrine 
differentiation. In contrast, we observed that expression of NGN3 could specify 
pancreatic endocrine cells from DE, as evidenced by the trend towards step wise 
induction of markers of endocrine specification (Figure 4.1). Furthermore, we 
demonstrated that HESC adopt a DE phenotype within 4 days of SOX17 activation. 
Lastly, we characterized the efficacy of the piggyBac transposon system for gene delivery 
in HESC and used this system to generate clonal double transgenic cell lines with
inducible activation of both SOX17 and PDX1.
Figure 4.1 Schematic representation of our findings in relation to pancreatic 
differentiation
This study used a transcription factor based approach for the differentiation of 
pancreatic endocrine progenitors from HESC. Pancreatic differentiation requires the 
initial specification of DE prior to downstream differentiation. We demonstrated that 
differentiation of DE from HESC requires 4 days of SOX17 activation. Following DE 
specification, constitutive expression of NGN3 generates pancreatic endocrine 
progenitor-like cells after 16 days of differentiation. Furthermore, we demonstrated that 
constitutive expression of PDX1 generates insulin positive cells following 16 days of 
differentiation, however these cells do not express any additional markers of pancreatic 











4.1.1 Contribution o f PAX4 expression to HESC differentiation
PAX4 is a transcription factor required for P-cell specification (Sosa-Pineda et al., 
1997). Therefore, we hypothesized that ectopic PAX4 expression could promote 
differentiation of endocrine progenitors from pluripotent HESC and DE cells. However, 
gene expression analysis of PAX4 over-expressing transgenic cell populations in both 
CA2 HESC and DE cells revealed no significant induction of any pancreatic, mesodermal 
or ectodermal markers (Figure 4.1.1).
Previous studies have shown that over-expression of Pax4 in mouse P-cells in vivo 
has a preventative effect against streptozotocin-induced hyperglycemia due to 
suppression of interleukin ip and cytochrome C (Hu He et ah, 2011; Lu et al., 2007). 
Additionally, in the neonatal rat pancreas, streptozotocin treatment induces Pax4 and 
Ngn3 expression in a-cells, resulting in dedifferentiation to endocrine progenitor cells that 
can contribute to pancreatic remodeling (Liang et al„ 2011). In rat pancreatic P-cells, 
adenoviral-mediated expression of Pax4 in vitro increased cell proliferation (Brun et al., 
2004). This correlated with induction of c-myc, a cell cycle regulator. Notably, though 
PAX4 has been implicated in the suppression of insulin and glucagon gene expression 
(Campbell et ah, 1999), however the previously described method of overexpression does 
not inhibit pancreatic hormone gene expression. Pax4 expression in mouse pancreatic 
epithelium and endocrine tissue resulted in death of the animals by 12 weeks due to 
progressive hyperglycemia (Collombat et ah, 2009). This study also demonstrated the 
ability of Pax4 expression to drive a-cells to a P-cell fate by generating transgenic mice 
that constitutively expressed Pax4 in a-cells. Within 1 week after birth, these mice
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displayed a 77% decrease in a-cell mass, and an increase in Pax4 positive, insulin 
positive cells that express (3-cell markers Nkx6.1, Pdxl and Glut2.
The above-mentioned studies demonstrate a role for Pax4 in late stage (3-cell 
development and transdifferentiation of a-cells to P-cells in both rats and mice. Each of 
these studies induced Pax4 expression in terminally differentiated cells, which is in 
contrast to our study which examined the effects of PAX4 expression in HESC-derived 
multipotent progenitors (Seguin et al., 2008). This may suggest that PAX4 requires 
binding partners and cofactors in order to be active that are not present prior to pancreatic 
cell specification. Additionally, PAX4 has been implicated as a transcriptional repressor 
of pancreatic hormones until the secondary transition at E13.5 (Smith et al., 1999). 
During development, PAX4 is expressed to specify P- and 8-cells, but is not expressed in 
the mature pancreas (Dohrmann et al., 2000). It is possible that constitutive expression of 
this transcriptional repressor in early cell types does not allow for differentiation to a 
pancreatic endocrine fate because it inhibits pancreatic hormone gene expression.
Transgenic mouse ES cells with constitutive Pax4 overexpression cultured in 
embryoid bodies generate approximately 60% cells with a P-cell like phenotype, with the 
remaining cells differentiating into a-cells (Blyszczuk et al., 2003). Additionally, mouse 
ES cells subjected to embryoid body-mediated cell differentiation to specify a 
mesendodermal progenitor prior to Pax4 nucleofection display expression of pancreatic 
endocrine markers Pdxl, somatostatin and produce insulin (Lin et al., 2007). In HESC, 
constitutive PAX4 overexpression during embryoid body differentiation for up to 21 days 
resulted in a small percentage of cells adopting a P-cell phenotype measured by
Figure 4.1.1 Contribution of PAX4 expression to directed cell differentiation
Schematic representation and summary of results obtained from PAX4 overexpressing 
cells. PAX4 expression does not induce any pancreatic, mesodermal or ectodermal 
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expression of Pdxl and insulin, in addition to release of C-peptide in response to 
tolbutamide (Liew et al., 2008).
Common to all of these studies is the combination of embryoid body-mediated 
differentiation with ectopic expression of Pax4. HESC require initial DE specification 
prior to further pancreatic differentiation (Wells and Melton, 1999). The above described 
studies have all relied on spontaneous embryoid body differentiation to specify definitive 
endoderm, however not all cells within the embryoid body will become DE, and therefore 
not all cells will be primed for differentiation to a pancreatic fate. Our study uses 
constitutive expression of SOX 17 in HESC in monolayer culture to specify a 
homogeneous population of DE prior to the introduction of PAX4 for further 
differentiation. While previous studies have noted differentiation to a (3-cell fate, our 
study does not observe any pancreatic differentiation. Though HESC with constitutive 
expression of SOX 17 are able to differentiate to a pancreatic fate using growth-factor 
mediated protocols (Seguin et al., 2008), it is possible that constitutive expression of 
SOX 17 could be preventing PAX4 from functioning appropriately in this context 
preventing transcription of its downstream targets. Additionally, by not culturing our 
HESC in embryoid bodies, we may be preventing cell-cell context that recapitulates how 
these cells differentiate in vivo.
4.1.2 Contribution ofPDXl expression to HESC differentiation
PDX1 is considered the master regulator of pancreatic development, as all 
pancreatic cells are derived from Pdxl positive progenitors (Gu et al., 2003). For this
109
reason, we assessed the ability of ectopic expression of PDX1 in pluripotent HESC and 
DE cells to specify the pancreatic endocrine fate. Our studies demonstrate that delivery of 
PDX1 in DE cells induced a significant upregulation of insulin gene expression within 16 
days, however these cells did not demonstrate the induction of any other markers of 
pancreatic specification (Figure 4.1.2).
Previous studies have demonstrated that inducible expression of Pdxl in mouse 
ES cells induces insulin gene expression when transgenic cells are cultured in embryoid 
bodies and first exposed to Activin A for endodermal differentiation, followed by Pdxl 
activation (Kubo et al., 2011). In rat mesenchymal stem cells, Pdxl overexpression 
reportedly resulted in insulin positive cells, however insulin was only at low levels (Yuan 
et al., 2010). Both of these studies are limited in their interpretation since cell 
differentiation was only assessed by measuring insulin gene expression, and therefore it is 
not clear if resultant cells also expressed other markers of pancreatic development. In 
contrast, PDX1 overexpression in human bone marrow derived mesenchymal stromal 
cells induces expression of various pancreatic endocrine markers including Pax4, Pax6, 
NeuroDl and Glut2 with some cells co-expressing insulin and c-peptide, however these 
cells did not secrete insulin at biologically significant levels (Limbert et al., 2011). 
Additionally, HESC with constitutive expression of PDX1 subjected to differentiation in 
embryoid bodies express pancreatic lineage markers such as Pax4, Ngn3 and Nkx2.2, 
however did not express insulin or glucagon following 30 days of differentiation in vitro 
(Lavon et al., 2006). Following transplantation of transgenic HESC into the kidney 
capsule of immunocompromised mice and subsequent differentition for 1 month, Pdxl
Schematic representation and summary of results obtained from PDX1 overexpressing 
cells. Ectopic PDX1 expression in CA2 HESC induces significant induction of markers 
of several lineages. This induction of early and late markers at the same timepoint 
suggests that there is a mixed population. In DE cells, ectopic PDX1 expression induces 
late pancreatic endocrine markers by 4 days without the induction of any other pancreatic 
lineage markers. By day 16, these cells have significant insulin gene expression, 
suggesting that these are insulin producing cells. (* significantly induced)
Figure 4.1.2: Contribution of PDX1 expression to directed cell differentiation
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expressing cells expressed insulin mRNA, while non-transgenic HESC did not. These 
results suggest that differentiation of P dxl-expressing HESC to a pancreatic endocrine 
fate requires signals present in the in vivo microenvironment. This requirement for 
appropriate in vivo microenvironment was also reported with mouse adipose tissue- 
derived stem cells engineered to express Pdxl\ these cells did not express any pancreatic 
markers in vitro, however when injected into the tail vein of streptozotocin treated mice, 
these cells were able to correct hyperglycemia in 20% of transplanted animals (Kajiyama 
et al., 2010).
During embryonic development, expression of Pdxl following endocrine 
commitment results in an increase in pancreatic p-cells and a decrease in a-cells (Yang et 
al., 2011). Furthermore, when Pdxl was expressed in embryonic and adult a-cells in 
vivo, there was a reduction in cells that expressed glucagon; however, only a small 
proportion of cells that lost glucagon expression gained insulin expression, suggesting 
that transdifferentiation was not efficient. In mouse and human ES cell-derived 
endoderm, biphasic induction of Pdxl expression promoted 30% of cells to adopt an 
endocrine cell fate (Bernardo et al., 2009). The resultant cells, however, expressed 
multiple islet hormones. Transdifferentiation of mouse pancreatic exocrine cells to cells 
that resemble P-cells has been demonstrated following co-expression of Pdxl, Ngn3 and 
MafA (Zhou et al., 2008). However, the efficiency of transdifferentiation was reported at 
only 20%.
It is important to note that while these studies have all reported the upregulation of 
insulin gene expression following ectopic PDX1 expression, only a subset of these studies 
also report the induction of pancreatic markers such as NGN3, NKX2.2 and during
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differentiation (Lavon et al., 2006; Limbert et al., 2011). While our data demonstrate that 
constitutive PDX1 expression in DE cells induces insulin gene expression, we did not 
demonstrate induction of any additional genes involved in pancreatic development.
PDX1 is a known regulator of insulin gene expression, occupying three different 
regions in the human insulin promoter and two regions in the mouse insulin promoter 
(Melloul et al., 2002). This is an important consideration in studies where insulin gene 
expression is reported as a marker P-cell differentiation without examining a broader 
panel of markers of different stages of pancreatic development to assess if cells are 
following the appropriate developmental pattern. It is possible that many of these studies 
have generated insulin producing cells, but not cells that have a functional P-cell 
phenotype. This may explain why the majority of these studies produce cells with 
minimal or no response to physiological glucose stimulation.
Interestingly, when PDX1 was constitutively expressed in pluripotent HESC, we 
observed induction of neurectodermal and mesendodermal markers. It has been shown in 
mouse ES cells that markers of pancreatic differentiation Pdxl, Ngn3, and Pax6 are 
expressed in ES-cell derived ectodermal cells (Roche et al., 2005). These ectodermal 
cells do not express insulin mRNA unless cultured in media conditioned by the rat 
insulinoma cell line INS-1. This is concurrent with our data where ectodermal markers 
SOX3 and NESTIN were upregulated during the early stages of PDX1-mediated 
differentiation during our differentiation process, suggesting some degree of 
neurectodermal differentiation. This demonstrates the importance of cell context prior to 
transcription factor introduction since DE cells are not competent to undergo ectodermal
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differentiation and therefore show no induction of neural markers following PDX1 
expression.
Analysis of transgene expression levels in SOX17 PDX1 HESC revealed 
considerable variation between transgenic populations. Population A demonstrated
100,000 fold increase in PDX1 expression vs undifferentiated controls at day 4, while 
population B had 1,200 fold induction and population C had a 4100 fold induction. 
Additionally, population A and C showed trends towards decreasing PDX1 expression 
over the time course, while population B demonstrated the opposite trend of increasing 
PDX1 expression. The inherent variation in transgene expression levels is likely due to 
both the number of integration events and the genomic site of PDX1 transgene insertion. 
Since the piggyBac system allows for transgene insertion at any TTAA site in the 
genome, it is possible that some copies of the transgene were inserted into 
heterochromatin and are therefore not actively expressed. Additionally, insertion site is 
important for the plasmid that confers rtTA expression, as this protein is required for 
PDX1 transcription. Some populations may have more rtTA expression, and therefore 
more protein for doxycycline to bind to, resulting in increased transgene expression. 
Importantly, these variations in PDX1 expression may have an effect on the resultant 
gene expression patterns in these cells in addition to cell morphology. Transgenic cell 
populations with higher PDX1 transgene expression may upregulate downstream PDX1 
targets that populations with lower PDX1 gene expression do not. Specifically, 
transgenic population A which demonstrated a 100,000 fold upregulation of PDX1 
transgene expression vs undifferentiated HESC may have overwhelmed the cell’s 
transcriptional machinery and prevented any further upregulation of gene expression.
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4.1.3 Contribution ofNGN3 expression to directed cell differentiation
All pancreatic endocrine cells are derived from NGN3 positive progenitors 
(Jensen et al., 2000; Smith et al., 2004). Because of this, we hypothesized that 
constitutive expression of NGN3 could be used to generate pancreatic endocrine cells 
from DE cells. Ectopic NGN3 expression in DE cells resulted in an obvious change in 
cell morphology, increasing the cytoplasmic to nuclear ratio and promoting the 
accumulation of cytoplasmic vacuoles after 8 days of differentiation. The presence of 
cytoplasmic vacuoles suggests there is active endo- or exocytosis activities within in these 
cells (Burgoyne and Morgan, 2003). These cytoplasmic vacuoles have the potential to be 
insulin secretory granules (Russ et al., 2011), as insulin gene expression shows a trend 
towards upregulation at this time point. Further analysis by both immunocytochemistry 
and scanning electron microscope (SEM) would be required to characterize these 
subcellular structures.
Through gene expression analysis, we also demonstrate a trend toward initiation 
of a transcriptional cascade associated with pancreatic development that involved 
downregulation of DE markers and upregulation of PAX4, PAX6, PDX1, NKX2.2, 
NKX6.1 and INS (Figure 4.1.3). These genes were activated in a sequential manner that 
mimicked biological pancreatic endocrine cell development, presumably due to the 
presence of an appropriate DE context prior to NGN3 expression. Though we observed 
sequential gene activation, we are assuming that this is occurring within the same cell 
population. However, we acknowledge that since this analysis was done at the population 
level, different cells within the population may be expressing subsets of these markers. 
Our findings correlate with previous studies of where NGN3 expression in
Figure 4.1.3: Contribution of NGN3 expression to directed cell differentiation
Schematic representation and summary of results obtained from NGN3 overexpressing 
cells. In CA2 HESC, ectopic expression of NGN3 induces markers of DE, late pancreatic 
markers, as well as pancreatic exocrine markers at day 4. Ectopic expression of NGN3 in 
DE cells induces a cascade of pancreatic markers that are expressed in a sequential order 
mimicking pancreatic development. These genes demonstrated a trend toward increased 






































progenitor cell types was shown to initiate expression of factors associated with the 
endocrine differentiation cascade (Gasa et al., 2004; Grapin-Botton et al., 2001; 
Heremans et al., 2002; Kubo et al., 2011; Lee et al., 2001; Limbert et al., 2011). 
Interestingly, although NGN3 positive progenitors were capable of generating all 
endocrine cell types during development, in our studies constitutive expression of NGN3 
in DE cells did not induce GCG or SST gene expression, suggesting the absence of a- or 
8- cell differentiation. These findings further suggest the induction of developmentally 
relevant endocrine cell differentiation using NGN3 expression since the resulting cell 
types do not demonstrate co-expression of multiple hormone mRNAs as reported in 
previous studies (Katsuta et al., 2010; Thorel et al., 2010).
Co-expression of Ngn3 and Pdxl in mouse ES-cell derived endoderm has been 
shown to induce the expression of pancreatic markers and promote insulin secretion. The 
resultant cells were not responsive to glucose, suggesting they are an immature form of 
pancreatic endocrine cells (Kubo et al., 2011). Ectopic NGN3 expression in human bone 
marrow derived mesenchymal stromal cells induced pancreatic gene expression, and 25% 
of cells were insulin positive, however insulin production was not significant (Limbert et 
al., 2011). Combined delivery of Pdxl and Ngn3 in mouse liver in vivo has been shown 
to induce insulin gene expression (Kaneto et al., 2005). Taken together, these studies 
demonstrate that co-expression of PDX1 and NGN3 can generate immature pancreatic 
cells. An alternative to simultaneous expression of both of these transcription is 
sequential activation. We have demonstrated that following SOX17-mediated DE 
specification, activation of NGN3 can specify endocrine progenitors. It is possible that 
subsequent expression of PDX1 in these cells could generate functional pancreatic cells.
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4.1.4 Comparison o f transcription factor- and growth factor- mediated pancreatic 
endocrine differentiation
Early studies using HESC to generate pancreatic cell types in vitro established that 
the generation of pancreatic precursor cells requires the initial specification of DE 
(D'Amour et al., 2006). To date this has been accomplished using various methods to 
generate DE from HESC such as activin A-mediated growth factor differentiation 
(D'Amour et al., 2005), as well as embryoid body formation (Liew et al., 2008). Activin 
A is known to induce DE differentiation in vertebrates, (Stainier, 2002); however, is only 
80% efficient in specifying DE from HESC (D'Amour et al., 2005). Conversely, 
culturing HESC in EBs results in spontaneous differentiation to all 3 primary germ layers 
and therefore has a lower efficiency than activin A-mediated differentiation. In general, 
these protocols results in the production of a heterogeneous population of cells, thereby 
limiting the number of cells that can go on to become pancreatic endocrine cells. 
Furthermore, while generation of DE using Activin A is more efficient than spontaneous 
EB differentiation, cell proliferation has been shown to be dramatically reduced with the 
onset of differentiation, thereby increasing the number of cells required for long-term 
differentiation. Alternatively, lineage-committed DE cells have been generated through 
constitutive expression of SOX17 in HESC (Seguin et al., 2008). This results in a 
homogeneous, proliferative population of cells receptive to signals for further 
differentiation to a variety of mature endoderm cell types including pancreatic cells.
Following DE specification, several strategies have been elucidated for the 
generation of P-cells. Stepwise protocols have been developed using sequential addition 
of developmentally relevant growth factors over long term in vitro culture to generate
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pancreatic p-cells (D'Amour et al., 2006; Jiang et al., 2007a; Jiang et al., 2007b; Nostro et 
al., 2011; Shim et al., 2007). Although these methods have been extensively 
characterized, they have limitations that are undesirable. These protocols produce a 
population of cells in which the P-cell phenotype comprises less than 15% of the final 
population (D'Amour et al., 2005). Researchers have optimized these growth factor- 
mediated approaches by manipulating key pathways in P-cell development, however 
despite these efforts the resultant populations contained only 25% C-peptide positive cells 
(Nostro et al., 2011). Alternatively, pancreatic exocrine cells have been transdifferentiated 
into pancreatic endocrine cells by in vivo viral-mediated gene delivery of the transcription 
factors MafA, Pdxl and Ngn3 (Zhou et al., 2008). The initial population of pancreatic 
exocrine cells is not self-renewable and the efficiency of transdifferentiation was only 
20% (Zhou et al., 2008). Previous studies have also described the ectopic expression of 
the transcription factors PDX1 (Kawasaki et al., 2008; Kubo et al., 2011; Lavon et al., 
2006; Limbert et al., 2011; Miyazaki et al., 2004), NGN3 (Kubo et al., 2011; Limbert et 
al., 2011; Serafimidis et al., 2008) and PAX4 (Blyszczuk et al., 2003; Liew et al., 2008) 
in various cell types including pancreatic ductal cells, pancreatic exocrine cells, and ES- 
derived endoderm cells in efforts to generate pancreatic endocrine cells.
4.1.5. Generation o f definitive endoderm through transient expression ofSOX17
Previous data has demonstrated that constitutive expression of SOX17 in HESC is 
sufficient to generate DE (Seguin et al., 2008). Additionally, it is known that during 
murine development Sox 17 is expressed concurrent with DE formation and is
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downregulated upon DE specification (Kanai-Azuma et al., 2002). Therefore, this study 
sought to characterize HESC with inducible activation of SOX17 in order to better mimic 
developmental patterns. We present data demonstrating that following 4 days of 
induction, SOX17-ER HESC adapt a DE phenotype, with significant expression of DE 
markers CER1, CXCR4 and DLX5. The timeframe of 4 days to specify DE from HESC 
is markedly shorter than 16 days to specify DE from the inner cell mass in a developing 
embryo. This may be due to the levels of SOX17 in the transgenic HESC, in addition to 
the monolayer culture that the cells are grown in permitting 4-OH Tamoxifen to bind to 
every cell resulting in subsequent differentiation. However, our current studies do not 
determine if 4 days of SOX 17 expression is sufficient to irreversibly commit HESC to the 
DE lineage. To determine if cells are committed, the transgene would have to be 
removed and cell potential analyzed following transgene removal. Additionally, previous 
reports of HESC with constitutive SOX17 expression were shown to demonstrate a 
mesendodermal phenotype, generating both mesoderm and endoderm tissue in a teratoma 
assay (Seguin et al., 2008). To determine if DE cells generated from transient SOX17 
activity are committed to the endoderm lineage, or if they adopt a mesendodermal 
phenotype like the HESC with constitutive expression of SOX17, a teratoma assay would 
have to be performed.
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4.1.6 Characterization o f the piggyBac transposase system in HESC and generation o f 
double transgenic HESC fo r pancreatic endocrine differentiation
The piggyBac transposase system used in these studies is a tet-inducible system 
for transient and reversible transgene delivery in mammalian cells (Ding et al., 2005). 
This system has been used to express c-Myc, Klf4, Sox2 and Oct4 to reprogram mouse 
fibroblasts to induced pluripotent stem cells (Woltjen et al., 2009). Through generation of 
PB-TET-GFP HESC, we determined that 500ng/mL doxycycline maximally induces 
transgene activity without affecting cell phenotype. Doses of doxycycline greater than 
500ng/mL may be cytotoxic to the cells, which could account for decreased gene 
expression. The piggyBac system is unique, as it allows for complete transgene removal, 
leaving no genetic footprint. Additionally, this inducible transgenic system does not 
require the generation of a fusion protein that could potentially affect gene function.
Once we characterized a second drug-inducible gene delivery system, we 
generated double transgenic HESC that had inducible expression of SOX 17 and PDX1. 
Expression of both SOX17 and PDX1 during embryonic development follow biphasic 
patterns of induction (Hui and Perfetti, 2002; Kanai-Azuma et al., 2002; Offield et al., 
1996), therefore an inducible model will allow us to better recapitulate developmental 
patterns of gene expression. We found clonal, double transgenic populations that express 
PDX1 at the level of, or greater than, human fetal pancreas.
4.2 Limitations of Research
For this study, we assayed the ability of three pancreatic transcription factors to 
drive specification of pancreatic endocrine cells from pluripotent cells, as well as cells
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that are committed to the definitive endoderm lineage. To do this, we generated 
transgenic cell populations through electroporation-mediated plasmid delivery and 
observed changes at the population level. Population analysis allowed us to develop a 
protocol for rapid, high throughput screening to assay the ability of individual pancreatic 
transcription factors to specify pancreatic endocrine cells but real-time PCR. One 
important limitation to this approach is that analysis was not conducted clonal cell 
populations. Consequently, all phenotypic analysis was conducted on a mixed population 
of cells due to factors such as the variation in the number of transgene integration events 
in each cell, as well as cell-cell communication within a heterogeneous population. 
Furthermore, given the disparity between transgene expression levels across the 
population, we cannot assume that differentiation was homogeneous. Furthermore, 
during development, pancreatic genes are temporally regulated, and disruption of this 
regulation can cause adverse effects. Constitutive expression of SOX17 to generate DE, 
followed by constitutive PAX4, PDX1 or NGN3 expression is an effective method for 
initial screening of these pancreatic genes, however it limits the ability to recapitulate 
complex and temporal developmental patterns of transcription factor activity.
The primary method used in these studies for characterization of novel transgenic 
HESC lines was quantitative gene expression analysis. This provided us with the ability 
to screen for markers of multiple lineages in a high-throughput manner. However, 
mRNA transcript levels do not always accurately reflect cellular protein levels due to 
post-transcriptional and translational regulation. In order to validate the changes in 
mRNA expression observed, functional analysis should be undertaken by immunoblotting 
or immunocytochemistry for markers such as insulin, glucagon and somatostatin. In
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addition, immunocytochemistry should be performed for the products of the transgenes 
PDX1, NGN3 and PAX4 to ensure that they are being translated into protein, and that the 
protein is localized to the nucleus for functional downstream transcriptional regulation.
4.3 Future Directions
The current studies present preliminary but promising evidence supporting the 
hypothesis that transcription factor expression can be used to efficiently direct the 
differentiation of HESC to a pancreatic endocrine phenotype. To further this study, I 
would generate clonal populations of HESC with inducible SOX17 activity using the 
ER12 system (Hayashi and McMahon, 2002) and NGN3 activity through the use of the 
piggyBac transposase system (Woltjen et al., 2009). This would allow for control of dose 
and duration of both definitive endoderm and pancreatic transcription factor activity.
Following the generation of these transgenic HESC, I would perform 
differentiation experiments maintaining cells in both monolayer culture and 3D culture 
using embryonic bodies (EB). The use of an EB system may better recapitulate cell-cell 
contact during development thereby enabling a more developmentally relevant context. 
Real-time PCR would be performed to assay gene expression, while 
immunocytochemistry would be performed for transgenes in addition to pancreatic 
hormones INS, GCG and SST. To determine the efficiency of differentiation, flow 
cytometry would be performed. Once a homogeneous population of pancreatic endocrine 
cells is generated, I would perform a teratoma assay to assess if the cells are committed to 
the pancreatic endocrine lineage.
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Once a source of pancreatic progenitors is obtained, I would transplant them into 
the tail vein in a mouse model of diabetes and track cell migration to see if these cells are 
functional and correct hyperglycemia. Injection in the tail vein allows access to 
vasculature and the cells are able to migrate to multiple tissues. A common problem with 
transplantation is the endogenous immune response that will destroy the transplanted 
cells. Commonly, cells are transplanted in immuno-compromised mice to avoid this 
problem. Alternatively, cells could be coated in alginate (Tuch et al., 2011), a semi­
permeable material that will allow for insulin to pass through, but prevent immune cells 
from destroying cell transplants. Polyethylene glycol coatings have also been studied as a 
method for delivering islet cells (Kizilel et al., 2010). Interestingly, cells encapsulated 
with polyethylene glycol can secrete more insulin compared to control islets.
Lastly, I would determine if the transplanted cells end up in the pancreas, or if 
they migrate to alternative tissues. To do this, I would label the cells with iron 
nanoparticles so that the animals could be live-imaged using MRI techniques (Tai et al., 
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